WO2020211872A1 - Fxr小分子激动剂及其制备方法和用途 - Google Patents

Fxr小分子激动剂及其制备方法和用途 Download PDF

Info

Publication number
WO2020211872A1
WO2020211872A1 PCT/CN2020/085713 CN2020085713W WO2020211872A1 WO 2020211872 A1 WO2020211872 A1 WO 2020211872A1 CN 2020085713 W CN2020085713 W CN 2020085713W WO 2020211872 A1 WO2020211872 A1 WO 2020211872A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
general formula
compound represented
400mhz
vii
Prior art date
Application number
PCT/CN2020/085713
Other languages
English (en)
French (fr)
Inventor
徐华强
李佳
施晶晶
臧奕
孙丹丹
刘明亮
谢荣荣
尤二利
高立信
谭倩
Original Assignee
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910969552.6A external-priority patent/CN111825667B/zh
Priority to EA202192872A priority Critical patent/EA202192872A1/ru
Priority to CA3137198A priority patent/CA3137198C/en
Priority to US17/603,823 priority patent/US20220213083A1/en
Priority to SG11202111502XA priority patent/SG11202111502XA/en
Priority to AU2020257379A priority patent/AU2020257379B2/en
Application filed by 中国科学院上海药物研究所 filed Critical 中国科学院上海药物研究所
Priority to KR1020217037613A priority patent/KR20220003558A/ko
Priority to BR112021020681A priority patent/BR112021020681A2/pt
Priority to MX2021012750A priority patent/MX2021012750A/es
Priority to JP2021562184A priority patent/JP7398605B2/ja
Priority to EP20791301.3A priority patent/EP3957640A4/en
Publication of WO2020211872A1 publication Critical patent/WO2020211872A1/zh
Priority to IL287159A priority patent/IL287159A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the invention relates to the field of medicine, and relates to a class of compounds as FXR agonists and their preparation and use. Specifically, it relates to a class of non-steroidal compounds that can be used as FXR agonists and their enantiomers, diastereomers, tautomers, solvates, prodrugs, or pharmaceutically acceptable
  • the accepted salt, its preparation method and its application in the preparation of drugs for treating FXR-related diseases are accepted salt, its preparation method and its application in the preparation of drugs for treating FXR-related diseases.
  • Nuclear receptors are widely present in organisms and are a type of nuclear transcription regulators that rely on specific ligand activation. Metabolic nuclear receptors are a type of nuclear receptors that regulate substance metabolism, cell proliferation, and apoptosis in the body. .
  • Farnesoid X receptor FXR is a member of the nuclear receptor superfamily. It was first discovered by Foman et al. in 1995. It is named because its transcriptional activity can be enhanced by farnesoid.
  • the FXR structure contains the amino-terminal ligand-independent transcription activation domain (AF1), DNA binding domain (DBD), hinge region, ligand binding domain (LBD) and the carbon-terminal ligand-dependent transcription activation domain (AF2).
  • AF1 amino-terminal ligand-independent transcription activation domain
  • DBD DNA binding domain
  • LBD ligand binding domain
  • AF2 carbon-terminal ligand-dependent transcription activation domain
  • Typical nuclear receptor structure FXR is activated by bile acids in the body and participates in the processes of bile acid metabolism, lipid metabolism, and sugar metabolism in the living body.
  • FXR regulates bile acid metabolism and transport mechanism mainly through the regulation of bile acid synthesis rate-limiting enzyme cholesterol 7 ⁇ -hydroxylase (cholesterol 7 ⁇ -hydroxylase, CYP7A1) transcription is completed, although FXR cannot directly act on the CYP7A1 promoter, it can induce small molecules
  • SHP small heterodimer partner
  • HNF-4 ⁇ hepatocyte nuclear factor 4 ⁇
  • LRH-1 liver receptor homolog
  • FXR in the liver directly or indirectly regulates PPAR ⁇ , VLDL receptor (very low density lipoprotein receptor, VLDLR), proprotein convertase subtilisin kexin type 9, PCSK9), and liver clear Doffer receptor (scavenger receptor group B type 1, SRB1), phospholipid transfer protein (PLTP), liver X receptor (LXR), sterol regulatory element binding protein-1C (sterol regulatory element) -binding protein-1C, SREBP-1C), fatty acid synthetase (FAS), activated lipoprotein lipase (LPL), etc., regulate lipid metabolism and transport to reduce plasma free fatty acids and triglycerides ester.
  • VLDL receptor very low density lipoprotein receptor, VLDLR
  • proprotein convertase subtilisin kexin type 9, PCSK9 proprotein convertase subtilisin kexin type 9, PCSK9
  • liver clear Doffer receptor scavenger receptor group B type 1, SRB1
  • PLTP phospholipid
  • FXR In the process of glucose metabolism, the activation of FXR can promote the synthesis of liver glycogen and increase insulin sensitivity and insulin secretion to control blood glucose levels in the body. Since FXR plays an important role in the processes of bile acid metabolism, lipid metabolism and glucose metabolism, FXR ligand small molecule compounds are expected to be used in the treatment of hypertriglyceridemia, type 2 diabetes, metabolic syndrome, and NAFLD. New medicine for disease treatment.
  • the purpose of the present invention is to provide a FXR small molecule agonist and its preparation method and application.
  • the first aspect of the present invention provides a compound represented by general formula I, or its enantiomers, diastereomers, tautomers, racemates, solvates, prodrugs Or a pharmaceutically acceptable salt thereof,
  • R 11 , R 12 , R 13 , R 14 , and R 15 are each independently hydrogen, halogen, halogenated C 1-6 alkyl, halogenated C 1 -C 6 alkoxy, C 1 -C 6 alkane Group, C 1-6 alkoxy, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkoxy, cyano or nitro;
  • R 2 is C 6 -C 12 aryl, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;
  • Q is a 4-8 membered heterocyclic group
  • A is the following substituted or unsubstituted groups: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, and the substitution means having a group selected from One group of two or three substituents: halogen, C 1 -C 6 alkyl, halo C 1-6 alkyl, halo C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl , C 1 -C 6 alkoxy, C 3 -C 6 cycloalkoxy;
  • X is O or S.
  • R 11 , R 12 , R 13 , R 14 , and R 15 are each independently hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl , Isobutyl, trifluoromethyl, or trifluoromethoxy.
  • R 12 , R 13 , and R 14 are hydrogen.
  • R 11 and R 15 are each independently hydrogen, chlorine, bromine, trifluoromethyl, or trifluoromethoxy.
  • R 2 is phenyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl or cyclopentyl.
  • Q is a 4-8 membered nitrogen-containing heterocyclic group or a 4-7 membered nitrogen-containing heterocyclic group.
  • A is the following substituted or unsubstituted group: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, the Substitution means having one or two substituents selected from the group consisting of fluorine, chlorine, bromine, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkoxy.
  • A is the following substituted or unsubstituted groups: phenyl, pyridyl, thienyl, furyl, indazolyl, indolyl, benzothienyl, benzofuranyl, preferably Ground,
  • A is a substituted or unsubstituted following group: phenyl, pyridyl, indolyl, and the substitution means having one or two substituents selected from the group consisting of fluorine, chlorine, bromine, trifluoromethyl Group, trifluoromethoxy, methyl, ethyl, propyl.
  • each substituent is the same or different.
  • A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • the pharmaceutically acceptable salt of the present invention refers to inorganic acids such as phosphoric acid, sulfuric acid, hydrochloric acid, or organic acids such as acetic acid, tartaric acid, citric acid, and malic acid, or aspartic acid, glutamine, etc. Salts formed by acidic amino acids such as acids, or salts formed with inorganic bases, such as sodium, potassium, calcium, aluminum and ammonium salts.
  • the compound is:
  • the compound of the present invention has an asymmetric center, a chiral axis, and a chiral plane, and can exist in the form of racemate, R-isomer, or S-isomer. Those skilled in the art can use conventional technical means to obtain R-isomer and/or S-isomer from racemate resolution.
  • the second aspect of the present invention provides a method for preparing the compound described in the first aspect, including the following steps:
  • X, R 2 , Q, A, R 11 , R 12 , R 13 , R 14 , and R 15 are as defined above.
  • the compound represented by formula VII is prepared by the following steps:
  • R 2 , Q, A, R 11 , R 12 , R 13 , R 14 , and R 15 are as defined above.
  • the compound represented by formula VII is prepared by the following steps:
  • R 2 , Q, A, R 11 , R 12 , R 13 , R 14 , and R 15 are as defined above.
  • composition comprising:
  • a pharmaceutically acceptable carrier is selected from:
  • the compound provided by the present invention can be used alone or mixed with pharmaceutically acceptable excipients (such as excipients, diluents, etc.) to prepare tablets, capsules, granules or syrups for oral administration.
  • pharmaceutically acceptable excipients such as excipients, diluents, etc.
  • the pharmaceutical composition can be prepared according to conventional methods in pharmacy.
  • the fourth aspect of the present invention provides the compound represented by the general formula I described in the first aspect, or its enantiomers, diastereomers, tautomers, racemates, and solvates.
  • the FXR-related disease is a disease related to bile acid metabolism, glucose metabolism, lipid metabolism, inflammation, and/or liver fibrosis.
  • the FXR-related diseases are non-alcoholic fatty liver (NASH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), gallstones, non-alcoholic Liver cirrhosis, liver fibrosis, cholestatic liver disease, hyperlipidemia, hypercholesterolemia or diabetes.
  • NASH non-alcoholic fatty liver
  • PBC primary biliary cirrhosis
  • PSC primary sclerosing cholangitis
  • gallstones non-alcoholic Liver cirrhosis
  • liver fibrosis cholestatic liver disease
  • hyperlipidemia hypercholesterolemia or diabetes.
  • Figure 1 shows the effects of compound 1 administration for 4 weeks on ALP in serum, hydroxyproline in liver, ⁇ -SMA and Col1 ⁇ 1 mRNA in liver, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001 and Compared with the model control group (vehicle group).
  • Figure 2 shows the effect of compound 1 administration for 4 weeks on the collagen content in liver pathological sections.
  • Figure 3 shows the effect of compound 8 administration for 3 weeks and 6 weeks on serum ALT, AST, TBA, LDH levels, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001 and the model control group (vehicle group) compared to.
  • Figure 4 shows the effect of compound 8 on the expression of ⁇ -SMA and Col1 ⁇ 1 mRNA in the liver for 6 weeks, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001 compared with the model control group (vehicle group).
  • Figure 5 shows the effect of compound 8 administration on the collagen content in liver pathological sections for 4 weeks, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001 compared with the model control group (vehicle group).
  • the inventor of the present application has developed a class of non-steroidal compounds that can be used as FXR agonists, which have the ability to agonize FXR at both the molecular and cellular levels.
  • the compounds of the present application can reduce serum levels
  • the levels of ALP, ALT, AST, TBA reduce the content of hydroxyproline in liver tissue, down-regulate the expression of ⁇ -SMA and Col1 ⁇ 1 mRNA in liver tissue, and reduce the collagen content in liver.
  • the compound of the present invention has the advantages of high FXR agonistic activity, simple synthesis, easy availability of raw materials, etc., and can be used to prepare drugs for treating FXR-related diseases. On this basis, the present invention has been completed.
  • the halogen is F, Cl, Br or I.
  • C 1 -C 6 means having 1, 2, 3, 4, 5 or 6 carbon atoms
  • C 1 -C 8 means having 1, 2, 3, 4, 5 , 6, 7, or 8 carbon atoms, and so on.
  • 3-10 membered means having 3-10 ring atoms, and so on.
  • alkyl refers to a saturated linear or branched hydrocarbon moiety.
  • C 1 -C 6 alkyl refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms. Restrictively include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl, etc.; preferably ethyl, propyl, isopropyl, Butyl, isobutyl, sec-butyl and tert-butyl.
  • alkoxy means -O-(C1-C6 alkyl) group.
  • C 1 -C 6 alkoxy refers to a linear or branched alkoxy group having 1 to 6 carbon atoms, including non-limiting methoxy, ethoxy, propoxy, isopropyl Oxy and butoxy etc.
  • cycloalkyl refers to a saturated cyclic hydrocarbon moiety.
  • C 3 -C 10 cycloalkyl refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring. Limits include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and the like.
  • C 3 -C 8 cycloalkyl “C 3 -C 7 cycloalkyl”
  • C 3 -C 6 cycloalkyl have similar meanings.
  • cycloalkoxy means cycloalkyl-O-, and cycloalkyl is as described above.
  • the term "4-7 membered nitrogen-containing heterocyclic group” refers to a cycloalkyl ring having 3-7 ring atoms and containing 1, 2 or 3 N atoms, including, without limitation, cyclopentane Alkane ring, cycloazahexane ring, cycloazaheptane ring, etc.
  • aryl means a hydrocarbyl moiety containing one or more aromatic rings.
  • C 6 -C 12 aryl group refers to an aromatic ring group having 6 to 12 carbon atoms that does not contain heteroatoms in the ring, such as phenyl, naphthyl and the like.
  • C 6 -C 10 aryl has a similar meaning. Examples of aryl groups include, but are not limited to, phenyl (Ph), naphthyl, pyrenyl, anthracenyl, and phenanthryl.
  • heteroaryl means a moiety containing one or more aromatic rings with at least one heteroatom (such as N, O or S), for example, the term “3-12 membered heterocyclic group” means A saturated or unsaturated 3-12-membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen on the ring, such as dioxolyl and the like.
  • heteroatom such as N, O or S
  • 3-12 membered heterocyclic group means A saturated or unsaturated 3-12-membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen on the ring, such as dioxolyl and the like.
  • 3-7 membered heterocyclyl has a similar meaning.
  • heteroaryl groups include furyl, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazolinyl, quinolinyl, isoquinolinyl and indole base.
  • heterocyclic group means a cyclic group containing at least one ring heteroatom (such as N, O or S), such as furyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazole Group, pyridyl, quinolinyl, isoquinolinyl, indolyl, pyrimidinyl, tetrahydropyridyl, pyrrolinyl, dihydropyridyl, dihydrofuranyl, dihydrothienyl, pyranyl.
  • heteroatom such as N, O or S
  • alkyl, alkoxy, cycloalkyl, heterocyclyl, and aryl groups described herein are substituted and unsubstituted groups.
  • Possible substituents on alkyl, alkoxy, cycloalkyl, heterocyclyl and aryl include, but are not limited to: hydroxyl, amino, nitro, nitrile, halogen, C1-C6 alkyl, C2-C10 alkene Group, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, C1-C6 alkoxy, aryl, heteroaryl Group, heteroaryloxy, C1-C10 alkylamino, C1-C20 dialkylamino, arylamino, diarylamino, C1-C10 alkylsulfamoyl, arylsul
  • the substitution is mono-substitution or poly-substitution
  • the poly-substitution is di-substitution, tri-substitution, tetra-substitution or penta-substitution.
  • the di-substitution refers to having two substituents, and so on.
  • the pharmaceutically acceptable salt of the present invention may be a salt formed by an anion and a positively charged group on the compound of formula I.
  • Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate Acid, glutamate, glucuronate, lactate, glutarate or maleate.
  • a salt can be formed from a cation and a negatively charged group on the compound of formula I. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion and ammonium ion, such as tetramethylammonium ion.
  • “pharmaceutically acceptable salt” refers to a salt formed by a compound of formula I and an acid selected from the group consisting of hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, Nitric acid, methanesulfonic acid, aminosulfonic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalic acid, pyruvic acid, malic acid , Glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid
  • the preparation method includes the following steps:
  • N-chlorosuccinimide N-chlorosuccinimide
  • the cyano compound represented by the general formula VII can also be prepared by the above route, including the following steps:
  • R 2 , R 11 , R 12 , R 13 , R 14 , R 15 , Q and A ring and X have the same definitions as above.
  • the base in steps a), b), d), a'), f) and g) is selected from the group consisting of triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, 1,8-diazide Heterobicycloundec-7-ene, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium ethoxide, potassium tert-butoxide, sodium tert-butoxide, butyl Lithium, lithium diisopropylamide;
  • the base in step b) is selected from triethylamine, diisopropylethylamine, pyridine, DBU, sodium carbonate, potassium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium ethoxide;
  • the reducing agent in step c) is selected from sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, lithium aluminum hydride, diisopropyl aluminum hydride, borane;
  • the copper catalyst in step e) is cuprous iodide, cuprous oxide, and cuprous sulfate;
  • the palladium catalyst is palladium acetate, tetrakis(triphenylphosphine) palladium, bis(acetonitrile) palladium(II) chloride, dichloride Palladium, tris(dibenzylideneacetone)dipalladium, bistriphenylphosphorus palladium dichloride, tris(dibenzylideneacetone)dipalladium-chloroform adduct, 1,1'-bis(diphenylphosphino) ) Ferrocene palladium(II) dichloride.
  • the present invention also provides a pharmaceutical composition, which contains active ingredients in a safe and effective amount, and a pharmaceutically acceptable carrier.
  • the “active ingredient” in the present invention refers to the compound of formula I in the present invention.
  • the "active ingredients” and pharmaceutical compositions of the present invention are used to prepare drugs for treating FXR-related diseases.
  • the "active ingredients” and pharmaceutical compositions of the present invention can be used as FXR agonists. In another preferred embodiment, it is used to prepare medicines for preventing and/treating diseases regulated by FXR agonists.
  • Safe and effective amount refers to: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects.
  • the pharmaceutical composition contains 1-2000 mg active ingredient/dose, more preferably, 10-200 mg active ingredient/dose.
  • the "one dose” is a tablet.
  • “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and sufficiently low toxicity. "Compatibility” here means that the components in the composition can be blended with the active ingredients of the present invention and between them without significantly reducing the efficacy of the active ingredients.
  • pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, and solid lubricants (such as stearic acid).
  • Magnesium stearate calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween) ), wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • vegetable oils such as soybean oil, sesame oil, peanut oil, olive oil, etc.
  • polyols such as propylene glycol, glycerin, mannitol, sorbitol, etc.
  • emulsifiers such as Tween
  • wetting agents such as sodium lauryl sulfate
  • coloring agents such as sodium lauryl sulfate
  • flavoring agents such as pepperminophen, sorbitol, etc.
  • antioxidants
  • the administration method of the active ingredient or the pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), etc.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-Butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
  • the composition may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
  • the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • suspending agents for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • composition for parenteral injection may contain physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • the compound of the present invention can be administered alone or in combination with other therapeutic drugs (such as hypolipidemic drugs).
  • other therapeutic drugs such as hypolipidemic drugs.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is the pharmaceutically effective dosage considered to be administered.
  • the daily The dosage is usually 1 to 2000 mg, preferably 20 to 500 mg.
  • the specific dosage should also consider factors such as the route of administration, the patient's health status, etc., which are within the skill range of a skilled physician.
  • the reagents and anhydrous solvents used were purchased from Chinese commercial companies. Unless otherwise specified, they were used directly; 1H and 13CNMR used BrukerAM-400 and Varian Mercury plus-400 nuclear magnetic resonance instruments, and mass spectrometry used Agilent 6230 mass spectrometer and 200- 300 mesh column chromatography silica gel (Qingdao Ocean Chemical Factory), HSGF254 TLC plate (Yantai Chemical Industry Research Institute).
  • Triethylamine (8.2 g) was added to methyl 3-cyclopropyl-3-oxopropionate (82 mmol) and stirred for 30 minutes. Then it was cooled to 10°C, and a solution of III-1 (18.3g, 82mmol) in absolute ethanol (80mL) was added dropwise (internal temperature not exceeding 30°C), and the reaction was left overnight at room temperature.
  • the reaction solution was diluted by adding ethyl acetate (100 mL), washed with water, and the aqueous phase was extracted with ethyl acetate (100 mL each time, 3 times in total). The organic phases were mixed, washed with saturated brine, and concentrated.
  • Dissolve IV-1 (21.6g, 69mmol) in tetrahydrofuran (140mL), cool to 0°C, slowly add a toluene solution of diisobutylaluminum hydride (1.5M, 102mL) to the solution, the reaction solution is at room temperature Stir for 6h.
  • reaction solution was slowly poured into ice water, and 1M aqueous hydrochloric acid solution was added to adjust the pH to about 2, ethyl acetate (100 mL each time, three times in total) was extracted, concentrated, and column chromatography to obtain the intermediate alcohol; this intermediate and triphenyl Phosphine (59 mmol) was dissolved in dichloromethane (60 mL), cooled to 0° C., under nitrogen protection, a solution of carbon tetrabromide (62 mmol) in dichloromethane (60 mL) was added dropwise, and reacted at room temperature for 4 h.
  • reaction solution was cooled to room temperature, diluted with water (5 mL), adjusted to pH approximately equal to 2 with 1M aqueous hydrochloric acid, and then extracted with ethyl acetate (4 mL each time, 3 times in total). The organic phases were combined, washed with saturated brine, concentrated and the crude product obtained was subjected to silica gel column chromatography to obtain the final product 1 (0.28 g, yield 64%).
  • Example 2 refers to the operation of Example 1. Starting from Intermediate VI-1, it is prepared via Route 1.
  • the synthetic route is as follows:
  • Example 3 With reference to the operation of Example 1, it was prepared from Intermediate V-1 through Route 1.
  • the synthetic route is as follows:
  • Example 4 With reference to the operation of Example 1, it was prepared from Intermediate VI-3 via Route 1.
  • the synthetic route is as follows:
  • Example 5 With reference to the operation of Example 1, it was prepared from Intermediate V-1 through Route 1.
  • the synthetic route is as follows:
  • Example 6 With reference to the operation of Example 1, it was prepared from Intermediate VI-5 via Route 1.
  • the synthetic route is as follows:
  • Example 7 With reference to the operation of Example 1, it was prepared from Intermediate V-1 through Route 1.
  • the synthetic route is as follows:
  • Example 8 Preparation of LXF-116 refers to the operation of Example 1, and is prepared from Intermediate II-8 via Route 1.
  • the synthetic route is as follows:
  • Example 9 refers to the operation of Example 1. Starting from Intermediate II-9, it is prepared via Route 1.
  • the synthetic route is as follows:
  • Example 10 The synthetic route of Example 10 is as follows:
  • the compound intermediate V-10 was synthesized according to the synthesis method of the compound V-1.
  • a solution of IX-10 1.3 g, 6.5 mmol
  • anhydrous tetrahydrofuran 20 ml
  • V-10 4.3 mmol
  • Water (20 mL) was added to the reaction solution, extracted with ethyl acetate (15 mL ⁇ 3), the organic phase was washed with saturated brine, concentrated, and column chromatography to obtain Intermediate VII-10 (1.21 g, yield 64%).
  • Example 11 The synthetic route of Example 11 is as follows:
  • the intermediate compound IV-11 was synthesized by using methyl isobutyryl acetate instead of methyl acetoacetate according to the synthesis method of compound IV-10 (yield 61%).
  • Example 12 The synthetic route of Example 12 is as follows:
  • Example 14 The synthetic route of Example 14 is as follows:
  • Example 15 The synthetic route of Example 15 is as follows:
  • Example 20 The synthetic route of Example 20 is as follows:
  • Example 24 The synthetic route of Example 24 is as follows:
  • Example 26 The synthetic route of Example 26 is as follows:
  • Example 30 The synthetic route of Example 30 is as follows:
  • Example 36 The synthetic route of Example 36 is as follows:
  • Example 40 The synthetic route of Example 40 is as follows:
  • Example 41 The synthetic route of Example 41 is as follows:
  • the recombinant GST-FXR fusion protein was used to determine the FXR activity with Perkin Elmer's AlphaScreen detection reagent.
  • the reaction of this method is in a 384-well plate, and the total reaction volume is 15 ⁇ L.
  • Protein, agonist, co-regulator, AlphaScreen Receptor beads and AlphaScreen The mixture of donor beads is reacted in a buffer containing: Tris-HCl 50mM (pH7.4), 50mM NaCl, BSA 0.1%, 1mM DTT, and the fluorescence signal intensity at 570nm wavelength is detected by the Envision fluorescence detector Reaction FXR activity.
  • the EC 50 value is calculated by the software Graphpad Prism 5.
  • the transfected cells were seeded on a 96-well flat-bottom microplate (ViewPlate-96, White 96) at a rate of 5*10 5 /well. -well Microplate with Clear Bottom, PerkinElmer). The cells were cultured for 24 hours to ensure the expression of the plasmid, and the test FXR receptor agonist was added; after the test compound was treated for 18 hours, the fluorescence intensity was measured using the luciferase kit (steady-Glo Luciferase Assay system) to reflect the compound's activation efficiency of the FXR receptor.
  • TAA induced liver fibrosis model rats were used to investigate the effect of long-term oral administration of Compound 1 on liver fibrosis in the model rats.
  • mice Male SD rats were intraperitoneally injected with thioacetamide (TAA, dissolved in normal saline) at a dose of 150 mg/kg three times a week to induce liver fibrosis model.
  • TAA thioacetamide
  • blood was taken from the retro-ocular venous plexus of the rats to detect serum ALP indicators.
  • the rats were randomly divided into 3 groups, each with 8 rats, which were respectively the model control group (Vehicle) , Compound 1 group (20mg/kg), positive compound OCA group (20mg/kg), etc., orally administered by gavage, once a day.
  • the animal s food intake and body weight were monitored.
  • the rats were taken from the retro-ocular venous plexus to detect the serum ALP index. After 4 weeks of administration, the rats were dislocated and sacrificed, and the liver was weighed. After the liver is heavy, part of the liver is fixed with 4% paraformaldehyde, and part of the liver is frozen at -80°C. During the whole experiment, 8 rats in the same litter were injected intraperitoneally with the same volume of saline as the system normal control group (WT).
  • WT system normal control group
  • This experiment is to detect the level of liver function index ALP in serum, the expression of ⁇ -SMA and Col1 ⁇ 1 (fibrosis-related genes) gene level in the liver, the content of hydroxyproline (a characteristic amino acid of collagen) in the liver, and liver pathological changes (days) Wolf scarlet staining) and other indicators reflect whether the compound has the effect of relieving liver fibrosis.
  • the research results show that the compound 1 of the present invention can significantly reduce the level of ALP in serum, reduce the content of hydroxyproline in liver tissue, and significantly down-regulate the expression of ⁇ -SMA and Col1 ⁇ 1 mRNA in liver tissue after 4 weeks of administration (Figure 1);
  • compound 1 can reduce the collagen content in the liver, because there are large differences within the model group, and there is no statistical difference (Figure 2).
  • long-term administration of compound 1 (LXF-32) of the present invention can significantly improve the liver function of TAA-induced hepatic fibrosis rats, down-regulate the expression of ⁇ -SMA and Col1 ⁇ 1 mRNA, and reduce the deposition of collagen in the liver. Fibrosis has a certain relief effect.
  • CCl4 induced liver fibrosis model mice were used to investigate the effect of long-term oral administration of Compound 8 on liver fibrosis in the model mice.
  • mice Male C57BL/6j mice were injected intraperitoneally with 2mL/kg, 10% CCl4 (dissolved in olive oil) three times a week to induce liver fibrosis model. Two weeks after modeling, blood was taken from the retro-ocular venous plexus of the mice to detect serum ALT, AST, TBA, LDH indicators. According to ALT, AST, TBA, LDH, body weight and other indicators, the mice were randomly divided into 5 groups.
  • mice in each group There are 10 animals in each group, namely the model control group (Vehicle), the compound 8 low-dose group (6mg/kg), the compound 8 high-dose group (20mg/kg), the positive compound OCA low-dose group (6mg/kg), OCA high
  • the dose group (20mg/kg), etc. were given by oral gavage, once a day.
  • the animals' food intake and body weight were monitored.
  • the mice were taken from the retro-ocular venous plexus to detect serum ALT, AST, TBA, LDH, and indicators.
  • the mice were dislocated and killed For mice, take the liver and weigh the liver. Take part of the liver and fix it with 4% paraformaldehyde.
  • liver fibrosis is analyzed by analyzing the levels of liver function indicators in serum, ALT, AST, TBA, LDH, the expression of ⁇ -SMA and Col1 ⁇ 1 gene levels in the liver, and liver pathological changes (Sirius scarlet staining). The role of.
  • the research results show that the compound 8 high and low dose groups of the present invention can significantly reduce the levels of ALT, AST and TBA in serum after 6 weeks of administration, and have little effect on LDH; the positive compound OCA high dose group can significantly reduce serum ALT, AST and TBA levels.
  • the low-dose group only had a lowering effect on TBA; the low-dose compound 8 had a slightly better effect than the low-dose group of OCA ( Figure 3).
  • Compound 8 high-dose group can significantly down-regulate the expression of ⁇ -SMA in the liver and down-regulate the expression of col1 ⁇ 1 in the liver (Figure 4); in the quantitative analysis of liver pathological sections stained with Sirius scarlet, both the high and low doses of compound 8 can significantly reduce the liver For collagen content, the effect of low-dose compound 8 is slightly better than that of the low-dose OCA group ( Figure 5).
  • long-term administration of compound 8 (LXF-116) of the present invention can significantly improve the liver function of CCl4-induced hepatic fibrosis mice, down-regulate the expression of ⁇ -SMA and Col1 ⁇ 1 mRNA, and reduce the deposition of collagen in the liver. Fibrosis has a better alleviating effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种FXR小分子激动剂及其制备方法和用途，结构如式(I)所示。式I化合物具备FXR激动活性，能够制备用于治疗FXR相关疾病的药物。

Description

FXR小分子激动剂及其制备方法和用途 技术领域
本发明涉及医药领域，涉及一类作为FXR激动剂的化合物及其制备和用途。具体而言，涉及一类可作为FXR激动剂的非甾体化合物及其对映异构体、非对映异构体、互变异构体、溶剂合物、前药、或其药学上可接受的盐，其制备方法以及其在制备治疗FXR相关疾病药物中的应用。
背景技术
核受体广泛存在生物体内，是一类依靠特异性配体激活的核转录调节因子，代谢性核受体是核受体中的一类，在体内调控者物质代谢、细胞增殖、凋亡等。法尼醇X受体(farnesoid X receptor,FXR)是核受体超家族的一员，最早于1995年由Foman等首次发现，因其转录活性可被法尼酯增强而命名。
FXR结构包含氨基端非配体依赖性的转录活化域(AF1)，DNA结合域(DBD)，铰链区，配体结合域(LBD)以及碳端配体依赖的转录活化域(AF2)，是典型的核受体结构。FXR在体内由胆汁酸激活，参与生命体中胆汁酸代谢、脂代谢、糖代谢等过程。FXR调控胆汁酸代谢和转运机制主要通过调控胆汁酸合成限速酶胆固醇7α羟化酶(cholesterol 7α-hydroxylase，CYP7A1)的转录完成，尽管FXR不能直接作用于CYP7A1启动子上，但是可诱导小分子异源二聚体伴侣(small heterodimer partner，SHP)的表达并结合HNF-4α(hepatocyte nuclear factor 4α，)以及LRH-1(liver receptor homolog)来下调CYP7A1的转录。脂代谢过程中，肝脏中FXR通过直接或间接调控PPARα，VLDL受体(very low density lipoprotein receptor，VLDLR)、前蛋白转化酶枯草溶菌素-9(proprotein convertase subtilisin kexin type 9，PCSK9)、肝脏清道夫受体(scavenger receptor group B type 1，SRB1)、磷脂转运蛋白(phosphor lipid transfer protein，PLTP)、肝脏X受体(liver X receptor，LXR)、固醇调节元件结合蛋白-1C(sterol regulatory element-binding protein-1C，SREBP-1C)和脂肪酸合成酶(fatty acid synthetase，FAS)、活化脂蛋白脂酶(lipoprotein lipase，LPL)等，调控脂质代谢和转运而达到降低血浆游离脂肪酸以及甘油三酯。在糖代谢过程中，FXR的激活能够促进肝脏糖原的合成以及增加胰岛素的敏感性及胰岛素分泌来控制体内血糖水平。由于FXR在胆汁酸代谢、脂代谢和糖代谢等过程中都起着重要的作用，FXR配体小分子化合物有望成为治疗高甘油三酯血症、2型糖尿病、代谢综合征以及NAFLD等代谢相关疾病治疗的新药。
发明内容
本发明的目的在于提供一种FXR小分子激动剂及其制备方法和用途。
本发明的第一方面，提供一种通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐，
Figure PCTCN2020085713-appb-000001
其中，R 11、R 12、R 13、R 14、R 15各自独立地为氢、卤素、卤代C 1-6烷基、卤代C 1-C 6烷氧基、C 1-C 6烷基、C 1-6烷氧基、C 3-C 6环烷基、C 3-C 6环烷氧基、氰基或硝基；
R 2为C 6-C 12芳基、C 1-C 6烷基或C 3-C 6环烷基；
Q为4-8元杂环基；
A为取代或未取代的以下基团：苯基、吡啶基、噻吩基、呋喃基、吲唑基、吲哚基、苯并噻吩基、苯并呋喃基，所述取代是指具有选自下组的一个两个、或三个取代基：卤素、C 1-C 6烷基、卤代C 1-6烷基、卤代C 1-C 6烷氧基、C 3-C 6环烷基、C 1-C 6烷氧基、C 3-C 6环烷氧基；
X为O或S。
在另一优选例中，R 11、R 12、R 13、R 14、R 15各自独立地为氢、氟、氯、溴、甲基、乙基、正丙基、异丙基、正丁基、异丁基、三氟甲基、或三氟甲氧基。
在另一优选例中，R 12、R 13、R 14为氢。
在另一优选例中，R 11、R 15各自独立地为氢、氯、溴、三氟甲基，三氟甲氧基。
在另一优选例中，R 2为苯基、甲基、乙基、正丙基、异丙基、正丁基、异丁基、环丙基、环丁基或环戊基。
在另一优选例中，Q为4-8元含氮杂环基或4-7元含氮杂环基。
在另一优选例中，Q为
Figure PCTCN2020085713-appb-000002
Figure PCTCN2020085713-appb-000003
在另一优选例中，A为取代或未取代的以下基团：苯基、吡啶基、噻吩基、呋喃基、吲唑基、吲哚基、苯并噻吩基、苯并呋喃基，所述取代是指具有选自下组的一个或两个取代基：氟、氯、溴、C 1-C 4烷基、C 3-C 6环烷基、C 1-C 4烷氧基、C 3-C 6环烷氧基。
在另一优选例中，A为取代或未取代的以下基团：苯基、吡啶基、噻吩基、呋喃基、吲唑基、吲哚基、苯并噻吩基、苯并呋喃基，较佳地，A为取代或未取代的以下基团： 苯基、吡啶基、吲哚基，所述取代是指具有选自下组的一个或两个取代基：氟、氯、溴、三氟甲基、三氟甲氧基、甲基、乙基、丙基。
本发明中，当具有两个或更多个取代基时，各取代基相同或不同。
在另一优选例中，A为
Figure PCTCN2020085713-appb-000004
在另一优选例中，本发明的药学上可接受的盐是指与磷酸、硫酸、盐酸等无机酸，或醋酸、酒石酸、柠檬酸、苹果酸等有机酸，或天冬氨酸、谷氨酸等酸性氨基酸形成的盐，或与无机碱形成的盐，如钠、钾、钙、铝盐和铵盐。
在另一优选例中，所述化合物为：
Figure PCTCN2020085713-appb-000005
Figure PCTCN2020085713-appb-000006
本发明的化合物具有不对称中心、手性轴和手性平面，并且可以以外消旋体、R-异构体或S-异构体的形式存在。本领域技术人员能够采用常规技术手段由外消旋体拆分获得R-异构体和/或S-异构体。
本发明的第二方面，提供第一方面所述的化合物的制备方法，包括以下步骤：
Figure PCTCN2020085713-appb-000007
(a’)通式VII所示的化合物与盐酸羟胺反应生成通式VIII所示的化合物；
(b’)通式VIII所示的化合物在光气、三光气、羰基二咪唑或者硫羰基二咪唑的作用下反应生成通式I所示的化合物，
其中，X、R 2、Q、A、R 11、R 12、R 13、R 14、R 15的定义如前所述。
在另一优选例中，通式VII所示的化合物通过以下步骤制备：
Figure PCTCN2020085713-appb-000008
a)以取代苯甲醛通式II所示的化合物为起始原料，与盐酸羟胺反应得到中间体后用N-氯代丁二酰亚胺(NCS)氯代后成通式III所示的化合物；
b)然后将通式III所示的化合物与3-氧代丙酸酯反应得到通式IV所示的化合物；
c)将通式IV所示的化合物中的酯还原下生成醇，再进行溴代后生成V所示的化合物，
d)通式V所示的化合物与Q-OH反应成通式VI所示的化合物；
e)通式VI所示的化合物在铜或者钯的催化下与Br-A-CN偶联得通式VII所示的化合物，
各式中，R 2、Q、A、R 11、R 12、R 13、R 14、R 15的定义如前所述。
在另一优选例中，通式VII所示的化合物通过以下步骤制备：
Figure PCTCN2020085713-appb-000009
f)Q-OH与F-A-CN反应生成通式IX所示的化合物；
g)通式V所示的化合物与通式IX所示的化合物反应生产通式VII所示的化合物，
各式中，R 2、Q、A、R 11、R 12、R 13、R 14、R 15的定义如前所述。
本发明的第三方面，提供一种药物组合物，包含：
第一方面所述的通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐；和
药学上可接受的载体。
本发明提供的化合物，可以单独使用，或者将其与可药用的辅料(例如赋形剂、稀释剂等)混合，配制成口服给药的片剂、胶囊剂、颗粒剂或糖浆剂等。该药物组合物可以按照制药学上常规方法制得。
本发明的第四方面，提供第一方面所述的通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐的用途，(a)用作FXR激动剂；
(b)用于制备用于治疗FXR相关疾病的药物；
(c)用于降低血清中ALP、ALT、AST、TBA的水平；
(d)用于降低肝脏组织中羟脯氨酸的含量；
(e)用于下调肝脏组织中α-SMA及Col1α1 mRNA表达；或
(f)用于减少肝脏中胶原含量。
在另一优选例中，所述FXR相关疾病为胆汁酸代谢、糖代谢、脂代谢、炎症、和/或肝脏纤维化过程相关疾病。
在另一优选例中，所述FXR相关疾病为非酒精性脂肪肝(NASH)、原发性胆汁性肝硬化(PBC)、原发性硬化性胆管炎(PSC)、胆结石、非酒精性肝硬化、肝纤维化、胆汁淤积性肝病、高血脂症、高胆固醇血症或糖尿病。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。说明书中所揭示的各个特征，可以被任何提供相同、均等或相似目的的替代性特征取代。限于篇幅，在此不再一一累述。
附图说明
图1为化合物1给药4周对血清中ALP、肝脏中羟脯氨酸、肝脏中α-SMA及Col1α1 mRNA的影响，*P<0.05，**P<0.01，***P<0.001与模型对照组(vehicle组)相比。
图2为化合物1给药4周对肝脏病理切片中胶原含量的影响。
图3为化合物8给药3周及6周对血清ALT、AST、TBA、LDH水平的影响，*P<0.05，**P<0.01，***P<0.001与模型对照组(vehicle组)相比。
图4为化合物8给6周对肝脏中α-SMA及Col1α1 mRNA表达的影响，*P<0.05，**P<0.01，***P<0.001与模型对照组(vehicle组)相比。
图5为化合物8给药4周对肝脏病理切片中胶原含量的影响，*P<0.05，**P<0.01，***P<0.001与模型对照组(vehicle组)相比。
具体实施方式
本申请的发明人经过广泛而深入地研究，研发出一类可作为FXR激动剂的非甾体化合物，在分子水平和细胞水平对FXR均有激动能力，研究表明本申请的化合物能够降低血清中ALP、ALT、AST、TBA的水平，降低肝脏组织中羟脯氨酸的含量，下调肝脏组织中α-SMA及Col1α1 mRNA表达，减少肝脏中胶原含量。本发明的化合物具有FXR激动活性高、合成简单、原料易得等优点，能够用于制备用于治疗FXR相关疾病的药物。在此基础上，完成了本发明。
术语
在本发明中，所述卤素为F、Cl、Br或I。
在本发明中，除非特别指出，所用术语具有本领域技术人员公知的一般含义。
在本发明中，术语“C 1-C 6”是指具有1、2、3、4、5或6个碳原子，“C 1-C 8”是指具有1、2、3、4、5、6、7或8个碳原子，依此类推。“3-10元”是指具有3-10个环原子，依此类推。
在本发明中，术语“烷基”表示饱和的线性或支链烃部分，例如术语“C 1-C 6烷基”是指具有1至6个碳原子的直链或支链烷基，非限制性地包括甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基和已基等；优选乙基、丙基、异丙基、丁基、异丁基、仲丁基和叔丁基。
在本发明中，术语“烷氧基”表示-O-(C1-C6烷基)基团。例如术语“C 1-C 6烷氧基”是指具有1至6个碳原子的直链或支链烷氧基，非限制性地包括甲氧基、乙氧基、丙氧基、异丙氧基和丁氧基等。
在本发明中，术语“环烷基”表示饱和的环状烃基部分，例如术语“C 3-C 10环烷基”是指在环上具有3至10个碳原子的环状烷基，非限制性地包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基和环癸基等。术语“C 3-C 8环烷基”、“C 3-C 7环烷基”、和“C 3-C 6环烷基”具有类似的含义。
在本发明中，术语“环烷氧基”表示环烷基-O-，环烷基如上所述。
在本发明中，术语“4-7元含氮杂环基”是指具有3-7个环原子且包含1、2或3个N原子 的环烷基环，非限制性地包括环氮戊烷环、环氮己烷环、环氮庚烷环等。
在本发明中，术语“芳基”表示包含一个或多个芳环的烃基部分。例如术语“C 6-C 12芳基”是指在环上不含杂原子的具有6至12个碳原子的芳香族环基，如苯基、萘基等。术语“C 6-C 10芳基”具有类似的含义。芳基的例子包括但不限于苯基(Ph)、萘基、芘基、蒽基和菲基。
在本发明中，术语“杂芳基”表示包含一个或多个具有至少一个杂原子(例如N,O或S)的芳环的部分，例如术语“3-12元杂环基”是指在环上含有1～3个选自氧、硫和氮中的杂原子的饱和或不饱和的3-12元环基，例如二氧杂环戊基等。术语“3-7元杂环基”具有类似的含义。杂芳基的例子包括呋喃基、芴基、吡咯基、噻吩基、噁唑基、咪唑基、噻唑基、吡啶基、嘧啶基、喹唑啉基、喹啉基、异喹啉基和吲哚基。
在本发明中，术语“杂环基”表示包含至少一个环杂原子(例如N,O或S)的环状基团，例如呋喃基、吡咯基、噻吩基、噁唑基、咪唑基、噻唑基、吡啶基、喹啉基、异喹啉基、吲哚基、嘧啶基、四氢吡啶基、吡咯啉基、二氢吡啶基、二氢呋喃基、二氢噻吩基、吡喃基。
除非另外说明，本文所述的烷基、烷氧基、环烷基、杂环基和芳基为取代的和未取代的基团。烷基、烷氧基、环烷基、杂环基和芳基上可能的取代基包括，但不限于：羟基、氨基、硝基、腈基、卤素、C1-C6烷基、C2-C10烯基、C2-C10炔基、C3-C20环烷基、C3-C20环烯基、C1-C20杂环烷基、C1-C20杂环烯基、C1-C6烷氧基、芳基、杂芳基、杂芳氧基、C1-C10烷基氨基、C1-C20二烷基氨基、芳基氨基、二芳基氨基、C1-C10烷基氨磺酰基、芳基氨磺酰基、C1-C10烷基亚氨基、C1-C10烷基磺基亚氨基、芳基磺基亚氨基、巯基、C1-C10烷硫基、C1-C10烷基磺酰基、芳基磺酰基、酰基氨基、氨酰基、氨基硫代酰基、胍基、脲基、氰基、酰基、硫代酰基、酰氧基、羧基和羧酸酯基。另一方面，环烷基、杂环烷基、杂环烯基、芳基和杂芳基也可互相稠合。
本发明中，所述取代为单取代或多取代，所述多取代为二取代、三取代、四取代、或五取代。所述二取代就是指具有两个取代基，依此类推。
本发明所述药学上可接受的盐可以是阴离子与式I化合物上带正电荷的基团形成的盐。合适的阴离子为氯离子、溴离子、碘离子、硫酸根、硝酸根、磷酸根、柠檬酸根、甲基磺酸根、三氟乙酸根、乙酸根、苹果酸根、甲苯磺酸根、酒石酸根、富马酸根、谷氨酸根、葡糖醛酸根、乳酸根、戊二酸根或马来酸根。类似地，可以由阳离子与式I化合物上的带负电荷的基团形成盐。合适的阳离子包括钠离子、钾离子、镁离子、钙离子和铵离子，例如四甲基铵离子。
在另一优选例中，“药学上可接受的盐”是指式I化合物同选自下组的酸形成的盐类：氢氟酸、盐酸、氢溴酸、磷酸、乙酸、草酸、硫酸、硝酸、甲磺酸、胺基磺酸、水杨酸、三氟甲磺酸、萘磺酸、马来酸、柠檬酸、醋酸、乳酸、酒石酸、琥珀酸、酢浆草酸、丙酮酸、苹果酸、谷氨酸、对甲苯磺酸、萘磺酸、乙磺酸、萘二磺酸、丙二酸、富马酸、丙酸、草酸、三氟乙酸、硬酯酸、扑酸、羟基马来酸、苯乙酸、苯甲酸、谷氨酸、抗坏血酸、对胺基苯磺酸、2-乙酰氧基苯甲酸和羟乙磺酸等；或者式I化合物与无机碱形成的钠盐、 钾盐、钙盐、铝盐或铵盐；或者通式I化合物与有机碱形成的甲胺盐、乙胺盐或乙醇胺盐。
制备方法
本发明的通式I所示的化合物的制备方法，合成路线如下：
Figure PCTCN2020085713-appb-000010
所述制备方法包括以下步骤：
a)以取代苯甲醛为起始原料在碱的作用下与盐酸羟胺反应得到中间体后用N-氯代丁二酰亚胺(NCS)氯代后成通式III所示的化合物；
b)然后将通式III所示的化合物在碱性条件下与相应的3-氧代丙酸酯反应为通式IV所示化合物；
c)通式IV所示的化合物中的酯在还原剂还原下生成相应的醇，醇进行溴代后生成V所示的化合物，
d)通式V所示的化合物在碱的作用下与Q-OH反应成通式VI所示的化合物；
e)通式VI所示的化合物在铜或者钯的催化下与Br-A-CN偶联得通式VII所示的氰基化合物；
a’)通式VII所示的化合物在碱的作用下盐酸羟胺反应生成通式VIII所示的化合物；
b’)通式VIII所示的化合物在光气、三光气、羰基二咪唑或者硫羰基二咪唑的作用下反应生成通式I所示的化合物。
Figure PCTCN2020085713-appb-000011
通式VII所示的氰基化合物也可采用以上路线制得，包括以下步骤：
f)在碱作用下Q-OH中的胺基取代F-A-CN中的氟生成化合物IX；
g)通式V所示的化合物在碱的作用下直接与制备好的IX反应成通式VI所示的化合物；
其中，R 2、R 11、R 12、R 13、R 14、R 15、Q和A环及X的定义同前。
步骤a)、b)、d)、a’)、f)及g)中的碱选自三乙胺、二异丙基乙胺、吡啶、4-二甲氨基吡啶、1,8-二氮杂二环十一碳-7-烯、碳酸钠、碳酸钾、氢氧化锂、氢氧化钠、氢氧化钾、甲醇钠、乙醇钠、乙醇钾、叔丁醇钾、叔丁醇钠、丁基锂、二异丙基氨基锂；
步骤b)中的碱选自三乙胺、二异丙基乙胺、吡啶、DBU、碳酸钠、碳酸钾、氢氧化锂、氢氧化钠、氢氧化钾、甲醇钠、乙醇钠、乙醇钾；
步骤c)中的还原剂选自硼氢化钠、三乙酰氧基硼氢化钠、氰基硼氢化钠、氢化锂铝、二异丙基氢化铝、硼烷；
步骤e)中的铜催化剂为碘化亚铜、氧化亚铜、硫酸亚铜；钯催化剂为醋酸钯、四(三苯基膦)钯，双(乙腈)氯化钯(II)、二氯化钯、三(二亚苄基丙酮)二钯、双三苯基磷二氯化钯、三(二亚苄基丙酮)二钯-氯仿加合物、1,1’-双(二苯膦基)二茂铁二氯化钯(II)。
药物组合物
本发明还提供了一种药物组合物，它包含安全有效量范围内的活性成分，以及药学上可接受的载体。
本发明所述的“活性成分”是指本发明所述的式I化合物。
本发明所述的“活性成分”和药物组合物用于制备治疗FXR相关疾病的药物。本发明所述的“活性成分”和药物组合物可用作FXR激动剂。在另一优选例中，用于制备预防和/治疗受FXR激动剂调节的疾病的药物。
“安全有效量”指的是：活性成分的量足以明显改善病情，而不至于产生严重的副作用。通常，药物组合物含有1-2000mg活性成分/剂，更佳地，含有10-200mg活性成分/剂。较佳地，所述的“一剂”为一个药片。
“药学上可接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的活性成分以及它们之间相互掺和，而不明显降低活性成分的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、 花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温
Figure PCTCN2020085713-appb-000012
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明的活性成分或药物组合物的施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)等。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性成分外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性成分外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
本发明化合物可以单独给药，或者与其他治疗药物(如降血脂药)联合给药。
使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂量通常为1～2000mg，优选20～500mg。当然，具体剂量还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件(如Sambrook等人，分子克隆：实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件)或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数是重量百分比和重量份数。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
所用仪器及主要实验材料如下：
所用试剂和无水溶剂从中国商业公司购买，除特别说明，均直接使用；1H和13CNMR用BrukerAM-400型和Varian Mercury plus-400型核磁共振仪，质谱采用Agilent 6230型质谱仪，及200-300目柱层析硅胶(青岛海洋化工厂)，HSGF254 TLC板(烟台市化工研究院)。
线路1
Figure PCTCN2020085713-appb-000013
线路2
Figure PCTCN2020085713-appb-000014
实施例1 LXF-32：
Figure PCTCN2020085713-appb-000015
中间体VI-1合成：
Figure PCTCN2020085713-appb-000016
0℃下将碳酸钾水溶液(3N，182mmol)逐滴加入搅拌中的盐酸羟胺(182mmol)的乙醇(100mL)溶液中，2,6-二氯苯甲醛(20g，114mmol)溶于100ml乙醇中，然后加入到羟胺溶液中，将温度升高到90℃，反应两小时。等待混合物冷却到室温然后浓缩至固体。加入水/乙醇(1000mL/100mL)溶液搅拌打碎固体，过滤，50℃下真空干燥过夜，得到化合物中间体(18.4g)。将此中间体溶于N,N-二甲基甲酰胺(50mL)，在0℃下逐滴加入N-氯代丁二酰亚胺(97mmol)的N,N-二甲基甲酰胺(100mL)溶液中，搅拌过夜。将反应液倒入0℃的冰水中，然后用甲基叔丁基醚(每次200mL，共3次)萃取，用饱和食盐水洗涤有机相，浓缩得到粗品。往装有粗品的烧瓶中加入正己烷(600mL)，利用磁子搅拌，过滤，将固体在真空下(30℃)干燥得到中间体III-1(18.3g，收率73％)。 1H NMR(400MHz,CDCl 3)δ7.43–7.39(m,2H),7.39–7.33(m,1H).
将三乙胺(8.2g)加入到3-环丙基-3-氧代丙酸甲酯(82mmol)中，搅拌30分钟。然后冷却到10℃，再将III-1(18.3g，82mmol)的无水乙醇(80mL)溶液逐滴加入其中(内温不超过30℃)，反应在室温下过夜。加入乙酸乙酯(100mL)稀释反应液，用水洗涤，并用乙酸乙酯(每次100mL，共3次)萃取水相。混合有机相，用饱和食盐水洗涤，浓缩。向浓缩物中加入100mL乙醚搅拌，真空下除去溶剂可得到固体产物IV-1(21.6g，收率84％)。 1HNMR(400MHz,CDCl 3)δ7.43–7.39(m,2H),7.39–7.33(m,1H),3.72(s,3H),2.21–2.09(m,1H),1.35–1.28(m,2H),1.25–1.18(m,2H).
将IV-1(21.6g，69mmol)溶于四氢呋喃(140mL)中，冷却到0℃，向溶液中缓慢滴加二异丁基氢化铝的甲苯溶液(1.5M,102mL)，反应液在室温下搅拌6h。将反应液缓慢倒 入冰水中，并加入1M盐酸水溶液调节pH约等于2，乙酸乙酯(每次100mL，共三次)萃取，浓缩，柱层析得到中间体醇；将此中间体和三苯基膦(59mmol)溶于二氯甲烷(60mL)中，冷却至0℃，在氮气保护下，逐滴加入四溴化碳(62mmol)的二氯甲烷(60mL)溶液，室温反应4h。将反应液除去溶剂得到油状物，经柱层析得到中间体V-1(15.3g收率96％)。 1HNMR(400MHz,CDCl 3)δ7.49–7.44(m,2H),7.43–7.37(m,1H),4.25(d,J＝1.3Hz,2H),2.21–2.09(m,1H),1.35–1.28(m,2H),1.25–1.18(m,2H).
在0℃下，向4-羟基哌啶-1-羧酸叔丁酯(1.3g，6.5mmol)的无水四氢呋喃(20mL)溶液中加入叔丁醇钾(6.5mmol)，搅拌30分钟，然后逐滴加入V-1(4.3mmol)的无水四氢呋喃(5mL)溶液，反应8h。向反应液中加入水(20mL)，用乙酸乙酯(每次15mL，共3次)萃取，有机相用饱和食盐水洗涤，浓缩，柱层析得到中间体4-((5-环丙基-3-(2,6-二氯苯基)异恶唑-4-基)甲氧基)哌啶-1-羧酸叔丁酯(1.55g)。将中间体4-((5-环丙基-3-(2,6-二氯苯基)异恶唑-4-基)甲氧基)哌啶-1-羧酸叔丁酯(1.55g，3.3mmol)溶于二氯甲烷(8mL)中，冷却至0℃，逐滴加入三氟乙酸(8mL)，室温搅拌3h。在真空下除去溶剂，加入乙酸乙酯(20mL)溶解，用2N氢氧化钠溶液，饱和食盐水洗涤，除去溶剂得到中间体VI-1(1.0g，收率72％)。 1HNMR(400MHz,CDCl 3)δ7.47–7.43(m,2H),7.42–7.36(m,1H),4.23(s,2H),3.55–3.49(m,1H),3.02–2.91(m,4H),2.10–2.02(m,1H),1.93–1.76(m,2H),1.75–1.62(m,2H),1.26–1.06(m,4H).
实施例化合物1即LXF-32合成：
Figure PCTCN2020085713-appb-000017
将中间体VI-1(1.0g，2.7mmol)，3-溴苯甲腈(4.1mmol)，叔丁醇钠(5.4mmol)，醋酸钯(0.14mmol)，1,1'-联萘-2,2'-双二苯膦(0.27mmol)加入到圆底烧瓶，在氮气保护下加入甲苯(80mL)，加热回流，反应过夜。将反应液冷却到室温，加水，萃取，浓缩，经柱层析得到中间体VII-1(0.55g，收率43％)。 1H NMR(400MHz,CDCl 3)δ7.40(d,J＝1.2Hz,1H),7.38(s,1H),7.32–7.28(m,2H),7.09–7.02(m,3H),4.34(s,2H),3.47–3.41(m,1H),3.31–3.20(m,2H),2.97–2.87(m,2H),2.18–2.11(m,1H),1.83–1.72(m,2H),1.26(qt,J＝10.1,5.1Hz,4H),1.13(ddd,J＝11.4,7.0,4.4Hz,2H).
将VII-1(0.4g，0.9mmol)，盐酸羟胺(2.3mmol)，无水乙醇(5mL)加入到圆底烧瓶中搅拌，缓慢滴加三乙胺(2.3mmol)，加热至80℃反应4h。冷却至室温，除去溶剂，用乙 酸乙酯(15mL)溶解，再用水，饱和食盐水洗涤，将有机相浓缩，经硅胶柱层析得到中间体3-(4-((5-环丙基-3-(2,6-二氯苯基)异恶唑-4-基)甲氧基)哌啶-1-基)-N'-羟基苯甲脒VIII-1(0.41g，收率96％)。
将3-(4-((5-环丙基-3-(2,6-二氯苯基)异恶唑-4-基)甲氧基)哌啶-1-基)-N'-羟基苯甲脒VIII-1(0.41g，0.83mmol)，N，N'-羰基二咪唑(1.0mmol)，1,4-二氧六环(4mL)加入圆底烧瓶，然后加入1,8-二氮杂双环[5.4.0]十一碳-7-烯(0.91mmol)，加热至100℃反应3小时。将反应液冷却至室温，加水(5mL)稀释，用1M盐酸水溶液调节pH约等于2，然后用乙酸乙酯萃取(每次4mL，共3次)。合并有机相，用饱和食盐水洗涤，浓缩所得粗品再经硅胶柱层析得到终产物1(0.28g收率64％)。 1H NMR(400MHz,CDCl 3)δ7.37(d,J＝7.5Hz,2H),7.31–7.26(m,2H),7.17(d,J＝10.4Hz,2H),7.07(d,J＝7.5Hz,1H),6.91(d,J＝7.6Hz,1H),4.33(s,2H),3.38(m,1H),3.21(m,2H),2.83(t,J＝8.6Hz,2H),2.15(m,1H),1.73(m,2H),1.51(m,2H),1.26(m,4H),1.13(m,2H).MS(ESI,m/z)：541[M+H] +。
实施例2：
Figure PCTCN2020085713-appb-000018
实施例2的制备参考实施例1的操作，从中间体VI-1出发通过路线1制备得到，合成路线如下：
实施例化合物2合成：
Figure PCTCN2020085713-appb-000019
从原料VI-1出发按照合成化合物1的合成方法合成化合物2，其中
白色固体VIII-2收率42％； 1H NMR(400MHz,CDCl 3)δ7.49(d,J＝8.7Hz,2H),7.36(d,J＝7.7Hz,2H),7.30–7.25(m,1H),6.81(d,J＝8.7Hz,2H),5.01(s,2H),4.34(s,2H),3.46–3.36(m,1H),3.33–3.22(m,2H),2.98–2.84(m,2H),2.20–2.12(m,1H),1.81–1.73(m,2H),1.59–1.48(m,2H),1.28–1.23(m,2H),1.15–1.08(m,2H).MS(EI,m/z)：501[M-H] +。
白色固体化合物2，收率71％， 1H NMR(400MHz,CDCl 3)δ7.64(d,J＝9.0Hz,2H), 7.44–7.36(m,2H),7.31(dd,J＝8.9,7.1Hz,1H),6.90(d,J＝9.1Hz,2H),4.37(s,2H),3.50(tt,J＝7.2,3.5Hz,1H),3.43–3.32(m,2H),3.13–2.99(m,2H),2.16(d,J＝30.8Hz,1H),1.85–1.73(m,2H),1.61–1.50(m,2H),1.32–1.25(m,4H),1.15(m,2H)；MS(ESI,m/z)：527[M+H] +。
实施例3：
Figure PCTCN2020085713-appb-000020
实施例3的制备参考实施例1的操作，从中间体V-1出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000021
在0℃下，向4-羟基六氢氮杂卓-1-羧酸叔丁酯(6.5mmol)的无水四氢呋喃(20mL)溶液中加入叔丁醇钾(6.5mmol)，搅拌30分钟，然后逐滴加入V-1(4.3mmol)的无水四氢呋喃(5mL)溶液，反应8h。向反应液中加入水(20mL)，用乙酸乙酯(每次15mL，共3次)萃取，有机相用饱和食盐水洗涤，浓缩，柱层析得到中间体。将中间体溶于二氯甲烷(8mL)中，冷却至0℃，逐滴加入三氟乙酸(8mL)，室温搅拌3h。在真空下除去溶剂，加入乙酸乙酯(20mL)溶解，用2N氢氧化钠溶液，饱和食盐水洗涤，除去溶剂得到中间体VI-3(0.87g，收率53％)。 1H NMR(400MHz,CDCl 3)δ7.45–7.40(m,2H),7.38–7.32(m,1H),4.35–4.23(m,2H),3.49–3.42(m,1H),3.40–3.18(m,4H),2.18–2.09(m,1H),1.83–1.59(m,5H),1.55–1.46(m,1H),1.28–1.23(m,2H),1.16–1.10(m,2H).
将中间体VI-3(0.8g)，4-溴苯甲腈(4.1mmol)，叔丁醇钠(5.4mmol)，醋酸钯(0.14mmol)，1,1'-联萘-2,2'-双二苯膦(0.27mmol)加入到圆底烧瓶，在氮气保护下加入甲苯(60mL)，加热回流，反应过夜。将反应液冷却到室温，加水，萃取，浓缩，经柱层析得到中间体VII-3(0.49g，收率48％) 1H NMR(400MHz,CDCl 3)δ7.44–7.40(m,2H),7.37–7.33(m,1H),7.27–7.21(m,1H),6.92–6.86(m,1H),6.83–6.78(m,2H),4.34–4.24(m,2H),3.49–3.43(m,1H),3.39–3.18(m,4H),2.18–2.10(m,1H),1.84–1.58(m,5H),1.55–1.48(m,1H),1.27–1.24(m,2H),1.15–1.09(m,2H).
从原料VII-3出发按照合成化合物1的合成方法合成化合物3，收率66％, 1H NMR(400MHz,CDCl 3)δ7.42–7.38(m,2H),7.36–7.31(m,1H),7.30–7.25(m,1H),7.03–6.99(m,2H),6.82–6.75(m,1H),4.35–4.23(m,2H),3.48–3.20(m,5H),2.18–2.10(m,1H),1.89–1.57(m,5H),1.55–1.45(m,1H),1.26–1.21(m,2H),1.15–1.08(m,2H).MS(ESI,m/z)：541[M+H] +。
实施例4：
Figure PCTCN2020085713-appb-000022
实施例4的制备参考实施例1的操作，从中间体VI-3出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000023
从原料VI-3出发按照合成化合物1的合成方法合成化合物4，其中
白色固体VII-4收率59％， 1H NMR(400MHz,CDCl 3)δ7.45–7.40(m,4H),7.37–7.32(m,1H),6.60(d,J＝9.1Hz,2H),4.33–4.24(m,2H),3.52–3.19(m,5H),2.17–2.09(m,1H),1.82–1.60(m,5H),1.51–1.43(m,1H),1.29–1.24(m,2H),1.15–1.09(m,2H).
白色固体化合物4收率69％， 1H NMR(400MHz,CDCl 3)δ7.60(d,J＝8.9Hz,2H),7.44–7.39(m,2H),7.38–7.33(m,1H),6.66(d,J＝9.1Hz,2H),4.35–4.23(m,2H),3.51–3.19(m,5H),2.18–2.08(m,1H),1.83–1.59(m,5H),1.54–1.45(m,1H),1.28–1.23(m,2H),1.15–1.08(m,2H).MS(ESI,m/z)：541[M+H] +。
实施例5：
Figure PCTCN2020085713-appb-000024
实施例5的制备参考实施例1的操作，从中间体V-1出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000025
Figure PCTCN2020085713-appb-000026
从原料V-1出发按照合成化合物1的合成方法合成化合物5，其中
胶状VI-5收率61％， 1H NMR(400MHz,CDCl 3)δ7.45–7.40(m,2H),7.39–7.32(m,1H),4.36–4.22(m,2H),3.98–3.92(m,1H),3.40–3.13(m,4H),2.17–2.08(m,1H),1.83–1.73(m,2H),1.31–1.24(m,2H),1.17–1.11(m,2H).
白色固体VII-5收率49％， 1H NMR(400MHz,CDCl 3)δ7.33(dd,J＝7.5,1.8Hz,1H),7.27–7.19(m,3H),6.94(d,J＝7.5Hz,1H),6.66–6.59(m,2H),4.40–4.28(m,2H),4.19–4.13(m,1H),3.35–3.18(m,3H),3.04(d,J＝10.5Hz,1H),2.18–2.09(m,1H),2.04–1.97(m,2H),1.30–1.25(m,2H),1.16–1.11(m,2H).
白色固体5收率63％， 1H NMR(400MHz,CDCl 3)δ7.33–7.13(m,4H),7.06(d,J＝7.8Hz,1H),6.83(s,1H),6.62–6.57(m,1H),4.39–4.29(m,2H),3.38–3.32(m,1H),3.31–3.19(m,2H),3.11(d,J＝10.3Hz,1H),2.18–2.10(m,1H),2.01–1.94(m,2H),1.26–1.22(m,2H),1.16–1.09(m,2H).MS(ESI,m/z)：513[M+H] +。
实施例6：
Figure PCTCN2020085713-appb-000027
实施例6的制备参考实施例1的操作，从中间体VI-5出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000028
从原料VI-5出发按照合成化合物1的合成方法合成化合物6，其中
白色固体VII-6收率38％。 1H NMR(400MHz,CDCl 3)δ7.46(d,J＝8.9Hz,2H),7.31(dd,J＝7.9,1.2Hz,1H),7.25(dd,J＝8.1,1.2Hz,1H),7.18(t,J＝7.9Hz,1H),6.40(d,J＝8.9Hz,2H),4.40–4.28(m,2H),4.19–4.12(m,1H),3.37–3.22(m,3H),3.11(d,J＝11.0Hz,1H),2.17–1.93(m,3H),1.31–1.26(m,2H),1.18–1.11(m,2H).
白色固体6收率69％。 1H NMR(400MHz,DMSO-d6)δ7.59(d,J＝8.8Hz,2H),7.54–7.39(m,3H),6.53(d,J＝8.8Hz,2H),4.32(q,J＝12.1Hz,2H),4.10(s,1H),3.31–3.23(m,2H),3.12–3.04(m,2H),2.39–2.28(m,1H),2.02–1.84(m,2H),1.15–1.06(m,4H).MS(ESI,m/z)：513[M+H] +。
实施例7：
Figure PCTCN2020085713-appb-000029
实施例7的制备参考实施例1的操作，从中间体V-1出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000030
从原料V-1出发按照合成化合物1的合成方法合成化合物7，其中
胶状VI-7收率67％。 1H NMR(400MHz,CDCl 3)δ7.42–7.39(m,2H),7.36–7.31(m,1H),4.27–4.18(m,2H),4.10–3.96(m,2H),3.53(t,J＝4.7Hz,1H),2.16–2.07(m,1H),1.91–1.69(m,6H),1.64(d,J＝14.4Hz,2H),1.26–1.22(m,2H),1.14–1.08(m,2H).
白色固体VII-7收率54％。 1H NMR(400MHz,CDCl 3)δ7.47–7.42(m,4H),7.38–7.34(m,1H),6.65(d,J＝8.9Hz,2H),4.26(s,2H),4.13–4.10(m,2H),3.46–3.41(m,1H),2.17–2.09(m,1H),1.97–1.81(m,6H),1.66–1.61(m,2H),1.28–1.25(m,2H),1.17–1.11(m,2H).
白色固体7收率77％。 1H NMR(400MHz,CDCl 3)δ7.60(d,J＝8.8Hz,2H),7.44–7.40(m,2H),7.37–7.32(m,1H),6.70(d,J＝9.0Hz,2H),4.25(s,2H),4.12–4.08(m,2H),3.42(s,1H),2.18–2.10(m,1H),1.99–1.82(m,6H),1.61(d,J＝14.4Hz,2H),1.26–1.22(m,2H),1.16–1.10(m,2H).MS(ESI,m/z)：553[M+H] +。
实施例8：
Figure PCTCN2020085713-appb-000031
实施例8即LXF-116的制备参考实施例1的操作，从中间体II-8出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000032
从原料II-8出发按照合成化合物1的合成方法合成化合物8，其中
白色固体IV-8收率58％。 1H NMR(400MHz,CDCl 3)δ7.82(d,J＝7.5Hz,1H),7.74–7.59(m,2H),7.56(d,J＝7.5Hz,1H),3.3.73(s,3H),2.19–2.09(m,1H),1.33–1.27(m,2H),1.24–1.15(m,2H)。
无色液体V-8收率88％。 1H NMR(400MHz,CDCl 3)δ7.84(d,J＝7.4Hz,1H),7.73–7.61(m,2H),7.57(d,J＝7.4Hz,1H),4.23(s,2H),2.17–2.09(m,1H),1.32–1.27(m,2H),1.23–1.17(m,2H).
胶状VI-8收率78％。 1H NMR(400MHz,CDCl 3)δ7.79(d,J＝7.0Hz,1H),7.66–7.56(m,2H),7.41(d,J＝7.0Hz,1H),4.23(s,2H),3.55–3.49(m,1H),3.03–2.91(m,4H),2.10–2.02(m,1H),1.94–1.77(m,2H),1.75–1.64(m,2H),1.25–1.07(m,4H).
白色固体VII-8收率48％。 1H NMR(400MHz,CDCl 3)δ7.77(d,J＝7.2Hz,1H),7.62–7.51(m,2H),7.48–7.40(m,3H),6.79(d,J＝9.0Hz,2H),4.27(s,2H),3.49–3.35(m,3H),3.12–2.96(m,2H),2.16–2.07(m,1H),1.85–1.70(m,2H),1.58–1.46(m,2H),1.23–1.18(m,2H),1.13–1.06(m,2H).
白色固体8收率72％。 1H NMR(400MHz,DMSO-d6)δ7.88(d,J＝7.6Hz,1H),7.80–7.67(m,2H),7.64–7.56(m,3H),6.99(d,J＝8.8Hz,2H),4.28(s,2H),3.46–3.37(m,3H),3.04–2.94(m,2H),2.35–2.25(m,1H),1.70(s,2H),1.41–1.27(m,2H),1.17–1.03(m,4H).MS(ESI,m/z)：527[M+H] +。
实施例9：
Figure PCTCN2020085713-appb-000033
实施例9的制备参考实施例1的操作，从中间体II-9出发通过路线1制备得到，合成路线如下：
Figure PCTCN2020085713-appb-000034
从原料II-9出发按照合成化合物1的合成方法合成化合物9，其中
白色固体IV-9收率59％。 1H NMR(400MHz,CDCl 3)δ7.66–7.50(m,2H),7.49–7.41(m,2H),3.70(s,2H),2.18–2.10(m,1H),1.31–1.26(m,2H),1.23–1.17(m,2H).
无色液体V-9收率82％。 1H NMR(400MHz,CDCl 3)δ7.65–7.52(m,2H),7.49–7.40(m,2H),4.36(s,2H),2.18–2.10(m,1H),1.31–1.26(m,2H),1.23–1.17(m,2H).
胶状VI-9收率80％。 1H NMR(400MHz,CDCl 3)δ7.45–7.30(m,4H),4.29–4.18(m,2H),2H),3.50–3.36(m,3H),3.12–3.00(m,2H),2.18–2.10(m,1H),1.86–1.76(m,2H),1.61–1.50(m,2H),1.28–1.22(m,2H),1.13–1.07(m,2H).
白色固体VII-9收率55％。 1H NMR(400MHz,CDCl 3)δ7.58–7.47(m,2H),7.45–7.34(m,4H),6.81(d,J＝9.0Hz,2H),4.28(s,2H),3.50–3.38(m,3H),3.14–3.00(m,2H),2.18–2.10(m,1H),1.85–1.76(m,2H),1.61–1.50(m,2H),1.27–1.22(m,2H),1.13–1.07(m,2H).
白色固体9收率69％。 1H NMR(400MHz,DMSO)δ7.69–7.48(m,6H),7.00(d,J＝8.9Hz,2H),4.37(s,2H),3.55–3.40(m,3H),3.06–2.96(m,2H),2.37–2.28(m,1H),1.80–1.69(m,2H),1.44–1.31(m,2H),1.16–1.03(m,4H).MS(EsI,m/z)：543[M+H] +。
实施例10：
Figure PCTCN2020085713-appb-000035
实施例10合成路线如下：
Figure PCTCN2020085713-appb-000036
在0℃下，将甲醇钠/甲醇溶液(5.4M，4.1mL)缓慢滴入的乙酰乙酸甲酯(22.2mmol)的无水四氢呋喃(10ml)溶液中，接着加入III-1(5g，22.2mmol)的无水四氢呋喃(10mL)溶液，在室温下搅拌12h。向反应液中加入乙酸乙酯(40mL)，用水，饱和食盐水洗涤有机相，除去溶剂得到油状物，再经柱层析得到中间体IV-10(3.4g，收率54％)。 1H NMR(400MHz,CDCl 3)δ7.45–7.41(m,2H),7.39–7.34(m,1H),3.71(s,3H),2.82(s,3H).
4-氟苯甲腈(2g，16.5mmol)，4-羟基哌啶(18.2mmol)，无水碳酸钾(41.3mmol)和DMSO(16mL)加入圆底烧瓶中，加热到130℃，反应12h。冷却至室温，加入30mL水，过滤，并用水洗涤固体得到中间体IX-10(3.1g，收率93％)。 1H NMR(400MHz,CDCl 3)δ7.52–7.43(m,2H),6.91–6.80(m,2H),4.00–3.91(m,1H),3.77–3.63(m,2H),3.13(ddd,J＝13.0,9.4,3.3Hz,2H),2.05–1.95(m,2H),1.70–1.59(m,2H).
从原料IV-10出发按照合成化合物V-1的合成方法合成化合物中间体V-10。在0℃下，向IX-10(1.3g，6.5mmol)的无水四氢呋喃(20ml)溶液中加入叔丁醇钾(6.5mmol)，搅拌30分钟，然后逐滴加入V-10(4.3mmol)的无水四氢呋喃(5mL)溶液，反应8h。向反应液中加入水(20mL)，用乙酸乙酯(15mL×3)萃取，有机相用饱和食盐水洗涤，浓缩，柱层析得到中间体VII-10(1.21g，收率64％)。 1H NMR(400MHz,CDCl 3)δ7.47(d,J＝9.0Hz,2H),7.42–7.38(m,2H),7.33–7.29(m,1H),6.80(d,J＝9.0Hz,2H),4.28(s,2H),3.51–3.43(m,1H),3.37–3.29(m,2H),3.12–2.97(m,2H),2.55(s,3H),1.78–1.72(m,2H),1.59–1.49(m,2H).
从原料VII-10出发按照合成化合物1的合成方法合成化合物10，白色固体收率64％。 1H NMR(400MHz,CDCl 3)δ7.64(d,J＝8.9Hz,2H),7.45–7.36(m,2H),7.34–7.28(m,1H),6.88(d,J＝8.9Hz,2H),4.29(s,2H),3.51–3.27(m,3H),3.14–2.99(m,2H),2.55(s,3H),1.85–1.70(m,2H),1.62–1.47(m,2H).MS(ESI,m/z)：501[M+H] +
实施例11：
Figure PCTCN2020085713-appb-000037
实施例11合成路线如下：
Figure PCTCN2020085713-appb-000038
从原料III-1出发按照合成化合物IV-10的合成方法用异丁酰基乙酸甲酯代替乙酰乙酸甲酯合成化合物中间体IV-11(收率61％)。 1H NMR(400MHz,CDCl 3)δ7.44–7.41(m,2H),7.38–7.33(m,1H),3.95–3.83(m,1H),3.69(s,3H),1.46(d,J＝7.0Hz,6H).
从原料IV-11出发按照合成化合物VII-10的合成方法合成化合物中间体VII-11。白色固体，收率71％； 1H NMR(400MHz,CDCl 3)δ7.43–7.38(m,2H),7.37–7.32(m,2H),7.28–7.23(m,1H),6.79–6.71(m,2H),4.23(s,2H),3.46–3.36(m,1H),3.34–3.23(m,2H),3.07–2.98(m,2H),1.73–1.63(m,2H),1.50–1.45(m,2H),1.38(d,J＝7.1Hz,6H).
从原料VII-11出发按照合成化合物1的合成方法合成化合物11。白色固体，收率66％. 1HNMR(400MHz,CDCl 3)δ7.63(d,J＝8.9Hz,2H),7.43–7.37(m,2H),7.34–7.27(m,1H),6.87(d,J＝9.0Hz,2H),4.29(s,2H),3.50–3.29(m,4H),3.12–2.98(m,2H),1.80–1.69(m,2H),1.59–1.47(m,2H),1.43(d,J＝7.0Hz,6H).MS(ESI,m/z)：529[M+H] +。
实施例12：
Figure PCTCN2020085713-appb-000039
实施例12合成路线如下：
Figure PCTCN2020085713-appb-000040
从原料III-1出发按照合成化合物IV-10的合成方法用苯甲酰基乙酸甲酯代替乙酰乙酸甲酯合成化合物中间体IV-12(收率67％)。 1H NMR(400MHz,CDCl 3)δ8.10(d,J＝7.9Hz,1H),7.97(d,J＝7.9Hz,1H),7.58–7.44(m,5H),7.41–7.36(m,1H),3.65(s,3H).
从原料IV-12出发按照合成化合物VII-10的合成方法合成化合物中间体VII-12。白色固体，收率74％； 1H NMR(400MHz,CDCl 3)δ7.95(dd,J＝7.8,1.7Hz,2H),7.64(d,J＝8.9Hz,2H),7.59–7.51(m,3H),7.49–7.44(m,2H),7.42–7.35(m,1H),6.90(d,J＝8.9Hz,2H),4.46(s,2H),3.57–3.50(m,1H),3.46–3.37(m,2H),3.12–2.99(m,2H),1.81–1.70(m,2H),1.62–1.49(m,2H).
从原料VII-12出发按照合成化合物1的合成方法合成化合物12。白色固体，收率56％. 1HNMR(400MHz,CDCl 3)δ11.50(s,1H),7.95(dd,J＝7.8,1.7Hz,2H),7.64(d,J＝8.9Hz,2H),7.59–7.51(m,3H),7.49–7.44(m,2H),7.42–7.35(m,1H),6.90(d,J＝8.9Hz,2H),4.46(s,2H),3.57–3.50(m,1H),3.46–3.37(m,2H),3.12–2.99(m,2H),1.81–1.70(m,2H),1.62–1.49(m,2H).MS(ESI,m/z)：562[M+H] +。
实施例13：
Figure PCTCN2020085713-appb-000041
实施例13合成路线如下：
Figure PCTCN2020085713-appb-000042
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-13。白色固体，收率94％； 1H NMR(400MHz,CDCl 3)δ8.37(d,J＝2.0Hz,1H),7.57(dd,J＝9.1,2.0Hz,1H),6.62(d,J＝9.1Hz,1H),4.16–3.93(m,3H),3.41–3.30(m,2H),2.00–1.91(m,2H),1.63–1.52(m,2H).
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-13。白色固体，收率74％； 1H NMR(400MHz,CDCl 3)δ8.26(d,J＝2.1Hz,1H),7.47(dd,J＝9.1,2.1Hz,1H),7.35–7.30(m,2H),7.27–7.22(m,1H),6.50(d,J＝9.1Hz,1H),4.27(s,2H),3.66–3.56(m,2H),3.45–3.40(m,1H),3.36–3.24(m,2H),2.13–2.04(m,1H),1.65–1.58(m,3H),1.45–1.35(m,2H),1.16–1.12(m,2H),1.07–1.00(m,2H).
从原料VII-13出发按照合成化合物1的合成方法合成化合物13。白色固体，收率71％； 1H NMR(400MHz,CDCl 3)δ8.52(d,J＝2.4Hz,1H),7.79(dd,J＝9.1,2.5Hz,1H),7.45–7.31(m,3H),6.67(d,J＝9.1Hz,1H),4.38(s,2H),3.81–3.67(m,2H),3.61–3.50(m,1H),3.46–3.33(m,2H),2.17(s,1H),1.82–1.68(m,2H),1.59–1.45(m,2H),1.31–1.27(m,2H),1.19–1.12(m,2H).MS(ESI,m/z)：528[M+H] +。
实施例14：
Figure PCTCN2020085713-appb-000043
实施例14合成路线如下：
Figure PCTCN2020085713-appb-000044
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-14。白色固体，收率91％； 1H NMR(400MHz,CDCl 3)δ8.26(d,J＝3.0Hz,1H),7.47(d,J＝8.8Hz,1H),7.09(dd,J＝8.8,3.0Hz,1H),4.03–3.95(m,1H),3.76–3.65(m,2H),3.25–3.14(m,2H),2.04–1.94(m,2H),1.73–1.60(m,2H).
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-14。白色固体，收率71％； 1H NMR(400MHz,CDCl 3)δ8.27(d,J＝2.7Hz,1H),7.50(d,J＝8.9Hz,1H),7.44–7.38(m,2H),7.37–7.29(m,1H),7.23–7.17(m,1H),4.27(s,2H),3.58–3.35(m,3H),3.24–3.14(m,2H),2.08–1.96(m,1H),1.84–1.77(m,2H),1.67–1.59(m,2H),1.30–1.25(m,2H),1.18–1.11(m,2H).
从原料VII-14出发按照合成化合物1的合成方法合成化合物14。白色固体，收率55％； 1H NMR(400MHz,CDCl 3)δ8.29(d,J＝2.7Hz,1H),7.89(d,J＝8.9Hz,1H),7.44–7.39(m,2H),7.33(d,J＝7.1Hz,1H),7.23–7.17(m,1H),4.37(s,2H),3.58–3.48(m,1H),3.42–3.35(m,2H),3.20–3.13(m,2H),2.20–2.12(m,1H),1.84–1.77(m,2H),1.64–1.57(m,2H),1.30–1.27(m,2H),1.18–1.12(m,2H).MS(ESI,m/z)：528[M+H] +。
实施例15：
Figure PCTCN2020085713-appb-000045
实施例15合成路线如下：
Figure PCTCN2020085713-appb-000046
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-15。白色固体，收率78％； 1H NMR(400MHz,CDCl 3)δ7.41–7.34(m,2H),6.96(d,J＝8.9Hz,1H),3.90–3.80(m,1H),3.18–3.10(m,2H),2.78–2.70(m,2H),2.26(s,3H),2.03–1.97(m,2H),1.77–1.67(m,2H).
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-15。白色固体，收率62％； 1H NMR(400MHz,CDCl 3)δ7.38–7.33(m,4H),7.30–7.25(m,1H),6.87(d,J＝8.2Hz,1H),4.32(s,2H),3.43–3.34(m,1H),2.94–2.85(m,2H),2.65–2.56(m,2H),2.20(s,3H),2.16–2.09(m,1H),1.82–1.74(m,2H),1.61–1.52(m,2H),1.22–1.18(m,2H),1.11–1.05(m,2H).
从原料VII-15出发按照合成化合物1的合成方法合成化合物15。白色固体，收率65％； 1H NMR(400MHz,CDCl 3)δ7.62(d,J＝1.7Hz,1H),7.59–7.54(m,1H),7.46–7.42(m,2H),7.38–7.32(m,1H),7.00(d,J＝8.4Hz,1H),4.38(s,2H),3.48–3.39(m,1H),3.03–2.94(m,2H),2.72–2.64(m,2H),2.31(s,3H),2.22–2.15(m,1H),1.89–1.80(m,2H),1.69–1.58(m,2H),1.31–1.28(m,2H),1.18–1.13(m,2H).MS(ESI,m/z)：541[M+H] +。
实施例16：
Figure PCTCN2020085713-appb-000047
实施例16合成路线如下：
Figure PCTCN2020085713-appb-000048
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-16。白色固体，收率78％； 1H NMR(400MHz,CDCl 3)δ7.38–7.30(m,1H),6.67–6.49(m,2H),4.02–3.91(m,1H),3.78–3.57(m,2H),3.26–3.04(m,2H),2.01–1.88(m,2H),1.68–1.55(m,2H).
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-16。白色固体，收率67％； 1H NMR(400MHz,CDCl 3)δ7.41–7.37(m,2H),7.37–7.28(m,2H),6.59–6.45(m,2H),4.34(s,2H),3.55–3.47(m,1H),3.37–3.28(m,2H),3.16–3.05(m,2H),2.19–2.10(m,1H),1.78–1.70(m,2H),1.59–1.48(m,2H),1.28–1.22(m,2H),1.16–1.10(m,2H)..
从原料VII-16出发按照合成化合物1的合成方法合成化合物16。白色固体，收率61％； 1H NMR(400MHz,CDCl 3)δ10.12(s,1H),7.71(t,J＝8.8Hz,1H),7.44–7.38(m,2H),7.35–7.30(m,1H),6.68(dd,J＝9.1,2.2Hz,1H),6.53(dd,J＝15.5,2.2Hz,1H),4.36(s,2H),3.56–3.47(m,1H),3.39–3.31(m,2H),3.16–3.07(m,2H),2.21–2.11(m,1H),1.81–1.74(m,2H),1.62–1.51(m,2H),1.32–1.27(m,2H),1.18–1.11(m,2H).MS(ESI,m/z)：545[M+H] +。
实施例17：
Figure PCTCN2020085713-appb-000049
实施例17合成路线如下：
Figure PCTCN2020085713-appb-000050
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-17。白色固体，收率55％； 1H NMR(400MHz,CDCl 3)δ6.43–6.32(m,2H),4.08–3.98(m,1H),3.71–3.62(m,2H),3.27–3.17(m,2H),2.02–1.94(m,2H),1.70–1.61(m,2H).
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-17。白色固体，收率67％； 1H NMR(400MHz,CDCl 3)δ7.43–7.39(m,2H),7.36–7.30(m,1H),6.34–6.27(m,2H),4.35(s,2H),3.60–3.50(m,1H),3.35–3.26(m,2H),3.19–3.08(m,2H),2.18–2.10(m,1H),1.74–1.68(m,2H),1.59–1.50(m,2H),1.28–1.25(m,2H),1.17–1.11(m,2H).
从原料VII-16出发按照合成化合物1的合成方法合成化合物17。白色固体，收率73％； 1H NMR(400MHz,CDCl 3)δ7.45–7.39(m,2H),7.37–7.31(m,1H),6.40(d,J＝13.5Hz,2H),4.36(s,2H),3.58–3.48(m,1H),3.36–3.27(m,2H),3.18–3.07(m,2H),2.22–2.10(m,1H),1.79–1.70(m,2H),1.61–1.52(m,2H),1.30–1.26(m,2H),1.18–1.12(m,2H).MS(ESI,m/z)：563[M+H] +。
实施例18：
Figure PCTCN2020085713-appb-000051
实施例18合成路线如下：
Figure PCTCN2020085713-appb-000052
Figure PCTCN2020085713-appb-000053
从原料4-羟基哌啶出发按照合成化合物IX-10的合成方法合成化合物中间体IX-18。白色固体，收率61％； 1H NMR(400MHz,DMSO)δ7.62–7.47(m,2H),7.08(t,J＝8.8Hz,1H),3.71–3.62(m,1H),3.43–3.37(m,2H),3.01–2.79(m,2H),1.92–1.74(m,2H),1.57–1.42(m,2H)。
从原料V-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-18。白色固体，收率63％； 1H NMR(400MHz,CDCl 3)δ7.43–7.38(m,2H),7.35–7.28(m,2H),7.26–7.21(m,1H),6.86(t,J＝8.6Hz,1H),4.35(s,2H),3.49–3.41(m,1H),3.26–3.15(m,2H),2.96–2.86(m,2H),2.20–2.12(m,1H),1.86–1.77(m,2H),1.65–1.55(m,2H),1.30–1.26(m,2H),1.16–1.09(m,2H)。
从原料VII-16出发按照合成化合物1的合成方法合成化合物18。白色固体，收率65％； 1H NMR(400MHz,CDCl 3)δ7.50–7.39(m,4H),7.36–7.30(m,1H),6.94(t,J＝8.5Hz, 1H),4.37(s,2H),3.55–3.42(m,1H),3.33–3.17(m,2H),3.00–2.84(m,2H),2.22–2.13(m,1H),1.89–1.80(m,2H),1.69–1.58(m,2H),1.32–1.26(m,2H),1.19–1.12(m,2H).MS(ESI,m/z)：545[M+H] +。
实施例19：
Figure PCTCN2020085713-appb-000054
实施例19合成路线如下：
Figure PCTCN2020085713-appb-000055
从原料VI-1出发按照合成化合物VII-1的合成方法合成化合物中间体VII-19。白色固体，收率37％； 1H NMR(400MHz,CDCl 3)δ7.67(s,1H),7.56(s,1H),7.37(d,J＝7.9Hz,2H),7.29–7.23(m,1H),7.09(d,J＝8.9Hz,1H),6.93(d,J＝8.9Hz,1H),4.31(s,2H),3.52(s,3H),3.37–3.27(m,1H),3.24–3.14(m,2H),2.83–2.71(m,2H),2.20–2.09(m,1H),1.86–1.75(m,2H),1.63–1.52(m,2H),1.26–1.18(m,2H),1.12–1.07(m,2H).
从原料VII-19出发按照合成化合物1的合成方法合成化合物19。白色固体，收率29％； 1H NMR(400MHz,DMSO-d6)δ7.81(s,1H),7.63(d,J＝7.7Hz,2H),7.55–7.50(m,1H),7.43(d,J＝9.0Hz,1H),7.28(s,1H),7.04(d,J＝9.0Hz,1H),4.33(s,2H),3.83(s,3H),3.35(s,1H),3.09(s,2H),2.80–2.72(m,2H),2.04–1.95(m,1H),1.75(s,2H),1.50–1.41(m,2H),1.20–1.07(m,4H).MS(ESI,m/z)：580[M+H] +。
实施例20：
Figure PCTCN2020085713-appb-000056
实施例20合成路线如下：
Figure PCTCN2020085713-appb-000057
将VIII-2(0.41g，0.83mmol)，N，N'-硫羰基二咪唑(1.0mmol)，1,4-二氧六环(4mL)加入圆底烧瓶，然后加入1,8-二氮杂双环[5.4.0]十一碳-7-烯(0.91mmol)，加热至100℃反应3小时。将反应液冷却至室温，加水(5mL)稀释，用1M盐酸水溶液调节pH约等于2，然后用乙酸乙酯萃取(每次4mL，共3次)。合并有机相，用饱和食盐水洗涤，浓缩所得粗品再经 硅胶柱层析得到终产物20(0.22g，收率49％)。 1H NMR(400MHz,CDCl 3)δ7.44–7.37(m,3H),7.34–7.30(m,1H),6.89(d,J＝8.9Hz,2H),4.36(s,2H),3.44–3.37(m,1H),3.24–3.14(m,2H),2.83–2.73(m,2H),2.21–2.14(m,1H),1.81–1.76(m,2H),1.61–1.54(m,2H),1.32–1.26(m,2H),1.17–1.09(m,2H).MS(ESI,m/z)：543[M+H] +。
实施例21：
Figure PCTCN2020085713-appb-000058
实施例21合成路线如下：
Figure PCTCN2020085713-appb-000059
从原料V-8和IX-13出发按照合成化合物VII-10的合成方法合成化合物中间体VII-21。白色固体，收率62％； 1H NMR(400MHz,CDCl 3)δ8.37(d,J＝1.1Hz,1H),7.79(d,J＝7.8Hz,1H),7.66–7.53(m,3H),7.46(d,J＝6.8Hz,1H),6.57(d,J＝9.1Hz,1H),4.28(s,2H),3.80–3.71(m,2H),3.54–3.46(m,1H),3.41–3.33(m,2H),2.16–2.08(m,1H),1.79–1.70(m,2H),1.55–1.45(m,2H),1.26–1.21(m,2H),1.14–1.08(m,2H)。
从原料VII-21出发按照合成化合物1的合成方法合成化合物21。白色固体，收率69％； 1H NMR(400MHz,DMSO)δ8.46(d,J＝2.1Hz,1H),7.86(d,J＝7.8Hz,1H),7.81–7.72(m,2H),7.68(t,J＝7.6Hz,1H),7.58(d,J＝7.6Hz,1H),6.85(d,J＝9.2Hz,1H),4.28(s,2H),3.81–3.70(m,2H),3.45(s,1H),3.25(t,J＝9.4Hz,2H),2.33–2.23(m,1H),1.75–1.61(m,2H),1.38–1.25(m,2H),1.17–1.04(m,4H).MS(ESI,m/z)：528[M+H] +。
实施例22：
Figure PCTCN2020085713-appb-000060
实施例22合成路线如下：
Figure PCTCN2020085713-appb-000061
从原料V-8和IX-14出发按照合成化合物VII-10的合成方法合成化合物中间体VII-22。白色固体，收率71％； 1H NMR(400MHz,CDCl 3)δ8.23(d,J＝2.7Hz,1H),7.78(d,J＝7.2Hz,1H),7.62–7.53(m,2H),7.49–7.43(m,2H),7.03(dd,J＝8.8,2.7Hz,1H),4.28(s,2H),3.53–3.46(m,1H),3.43–3.36(m,2H),3.18–3.10(m,2H),2.15–2.07(m, 1H),1.83–1.75(m,2H),1.62–1.52(m,2H),1.24–1.20(m,2H),1.15–1.09(m,2H)。
从原料VII-22出发按照合成化合物1的合成方法合成化合物22。白色固体，收率66％； 1H NMR(400MHz,DMSO)δ8.33(d,J＝2.3Hz,1H),7.85(d,J＝7.7Hz,1H),7.78–7.64(m,3H),7.59(d,J＝7.5Hz,1H),7.32(dd,J＝9.0,2.3Hz,1H),4.29(s,2H),3.50–3.36(m,3H),3.06(t,J＝9.1Hz,2H),2.34–2.23(m,1H),1.79–1.68(m,2H),1.46–1.33(m,2H),1.14–1.04(m,4H).MS(ESI,m/z)：528[M+H] +。
实施例23：
Figure PCTCN2020085713-appb-000062
实施例23合成路线如下：
Figure PCTCN2020085713-appb-000063
从原料V-8和IX-18出发按照合成化合物VII-10的合成方法合成化合物中间体VII-23。白色固体，收率70％； 1H NMR(400MHz,CDCl 3)δ7.84–7.79(m,1H),7.66–7.56(m,2H),7.49(d,J＝6.8Hz,1H),7.35(dd,J＝8.4,1.3Hz,1H),7.28–7.24(m,1H),6.87(t,J＝8.4Hz,1H),4.29(s,2H),3.49–3.38(m,1H),3.32–3.23(m,2H),2.97–2.88(m,2H),2.18–2.09(m,1H),1.90–1.82(m,2H),1.68–1.59(m,2H),1.29–1.25(m,2H),1.17–1.10(m,2H)。
从原料VII-23出发按照合成化合物1的合成方法合成化合物23。白色固体，收率61％； 1H NMR(400MHz,DMSO)δ7.91(d,J＝7.7Hz,1H),7.83–7.70(m,2H),7.60(d,J＝7.5Hz,1H),7.56–7.47(m,2H),7.14–7.07(m,1H),4.29(s,2H),3.44–3.33(m,1H),3.18–3.09(m,2H),2.88–2.79(m,2H),2.37–2.29(m,1H),1.82–1.73(m,2H),1.50–1.39(m,2H),1.18–1.06(m,4H).MS(ESI,m/z)：545[M+H] +。
实施例24：
Figure PCTCN2020085713-appb-000064
实施例24合成路线如下：
Figure PCTCN2020085713-appb-000065
从原料V-8和IX-16出发按照合成化合物VII-10的合成方法合成化合物中间体VII-24。白色固体，收率70％； 1H NMR(400MHz,CDCl 3)δ7.82–7.75(m,1H),7.64–7.54 (m,2H),7.47–7.43(m,1H),7.38–7.31(m,1H),6.57(dd,J＝8.9,2.4Hz,1H),6.48(dd,J＝13.3,2.4Hz,1H),4.28(s,2H),3.52–3.45(m,1H),3.43–3.34(m,2H),3.15–3.04(m,2H),2.16–2.07(m,1H),1.83–1.72(m,2H),1.59–1.49(m,2H),1.25–1.20(m,2H),1.15–1.09(m,2H)。
从原料VII-24出发按照合成化合物1的合成方法合成化合物24。白色固体，收率61％； 1H NMR(400MHz,DMSO)δ7.89(d,J＝7.7Hz,1H),7.81–7.68(m,2H),7.59(d,J＝7.5Hz,1H),7.52(t,J＝8.9Hz,1H),6.85(dd,J＝10.2,7.5Hz,2H),4.28(s,2H),3.48–3.39(m,3H),3.11–3.00(m,2H),2.38–2.27(m,1H),1.75–1.65(m,2H),1.39–1.27(mS,2H),1.17–1.05(m,4H).MS(ESI,m/z)：545[M+H] +。
实施例25：
Figure PCTCN2020085713-appb-000066
实施例25合成路线如下：
Figure PCTCN2020085713-appb-000067
从原料V-8和IX-17出发按照合成化合物VII-10的合成方法合成化合物中间体VII-25。白色固体，收率59％； 1H NMR(400MHz,CDCl 3)δ7.79–7.76(m,1H),7.64–7.54(m,2H),7.47–7.43(m,1H),6.30(d,J＝11.7Hz,2H),4.27(s,2H),3.54–3.46(m,1H),3.40–3.30(m,2H),3.18–3.06(m,2H),2.16–2.05(m,1H),1.82–1.70(m,2H),1.57–1.49(m,2H),1.23–1.18(m,2H),1.14–1.07(m,2H)。
从原料VII-25出发按照合成化合物1的合成方法合成化合物25。白色固体，收率64％； 1H NMR(400MHz,DMSO)δ7.89(d,J＝7.7Hz,1H),7.80–7.68(m,2H),7.60(d,J＝7.4Hz,1H),6.77(d,J＝13.3Hz,2H),4.29(s,2H),3.50–3.38(m,3H),3.18–3.03(m,2H),2.37–2.25(m,1H),1.78–1.64(m,2H),1.43–1.27(m,2H),1.20–1.03(m,4H).MS(ESI,m/z)：563[M+H] +。
实施例26：
Figure PCTCN2020085713-appb-000068
实施例26合成路线如下：
Figure PCTCN2020085713-appb-000069
从原料V-9和IX-13出发按照合成化合物VII-10的合成方法合成化合物中间体VII-26。白色固体，收率67％； 1H NMR(400MHz,CDCl 3)δ8.37(s,1H),7.60–7.47(m,3H),7.41–7.34(m,2H),6.57(d,J＝9.1Hz,1H),4.41(s,2H),3.85–3.73(m,2H),3.60–3.50(m,1H),3.43–3.32(m,2H),2.19–2.09(m,1H),1.81–1.73(m,2H),1.57–1.47(m,2H),1.25–1.20(m,2H),1.14–1.07(m,2H)。
从原料VII-26出发按照合成化合物1的合成方法合成化合物26。白色固体，收率68％； 1H NMR(400MHz,DMSO)δ8.46(d,J＝2.3Hz,1H),7.80(dd,J＝9.1,2.3Hz,1H),7.69–7.61(m,2H),7.57–7.49(m,2H),6.92(d,J＝9.2Hz,1H),4.38(s,2H),3.88–3.75(m,2H),3.57–3.47(m,1H),3.32–3.21(m,2H),2.37–2.27(m,1H),1.77–1.67(m,2H),1.38–1.27(m,2H),1.16–1.05(m,4H).MS(ESI,m/z)：544[M+H] +。
实施例27：
Figure PCTCN2020085713-appb-000070
实施例27合成路线如下：
Figure PCTCN2020085713-appb-000071
从原料V-9和IX-14出发按照合成化合物VII-10的合成方法合成化合物中间体VII-27。白色固体，收率74％； 1H NMR(400MHz,CDCl 3)δ8.23(s,1H),7.58–7.43(m,3H),7.37(d,J＝7.8Hz,2H),7.03(dd,J＝8.8,2.7Hz,1H),4.40(s,2H),3.57–3.50(m,1H),3.48–3.38(m,2H),3.19–3.09(m,2H),2.17–2.08(m,1H),1.87–1.75(m,2H),1.65–1.54(m,2H),1.24–1.18(m,2H),1.13–1.07(m,2H)。
从原料VII-27出发按照合成化合物1的合成方法合成化合物27。白色固体，收率61％； 1H NMR(400MHz,DMSO)δ8.34(d,J＝2.4Hz,1H),7.71(d,J＝8.9Hz,1H),7.67–7.58(m,2H),7.52–7.46(m,2H),7.33(dd,J＝8.9,2.1Hz,1H),4.38(s,2H),3.56–3.42(m,3H),3.07(t,J＝9.3Hz,2H),2.34–2.23(m,1H),1.83–1.72(m,2H),1.49–1.37(m,2H),1.14–1.03(m,4H).MS(ESI,m/z)：544[M+H] +。
实施例28：
Figure PCTCN2020085713-appb-000072
实施例28合成路线如下：
Figure PCTCN2020085713-appb-000073
从原料V-9和IX-18出发按照合成化合物VII-10的合成方法合成化合物中间体VII-28。白色固体，收率67％； 1H NMR(400MHz,CDCl 3)δ7.60–7.56(m,1H),7.55–7.49(m,1H),7.41–7.37(m,2H),7.33(d,J＝8.4Hz,1H),7.25(d,J＝12.7Hz,1H),6.87(t,J＝8.6Hz,1H),4.41(s,2H),3.51–3.42(m,1H),3.34–3.23(m,2H),2.97–2.88(m,2H),2.20–2.11(m,1H),1.91–1.82(m,2H),1.70–1.59(m,2H),1.25–1.22(m,2H),1.15–1.08(m,2H)。
从原料VII-28出发按照合成化合物1的合成方法合成化合物28。白色固体，收率72％； 1H NMR(400MHz,DMSO)δ7.69–7.62(m,2H),7.57–7.46(m,4H),7.10(t,J＝8.7Hz,1H),4.37(s,2H),3.48–3.40(m,1H),3.24–3.11(m,2H),2.85(t,J＝9.2Hz,2H),2.40–2.25(m,1H),1.87–1.75(m,2H),1.56–1.40(m,2H),1.16–1.04(m,4H).MS(ESI,m/z)：561[M+H] +。
实施例29：
Figure PCTCN2020085713-appb-000074
实施例29合成路线如下：
Figure PCTCN2020085713-appb-000075
从原料V-9和IX-16出发按照合成化合物VII-10的合成方法合成化合物中间体VII-29。白色固体，收率72％； 1H NMR(400MHz,CDCl 3)δ7.57–7.47(m,2H),7.41–7.30(m,3H),6.57(dd,J＝8.9,2.4Hz,1H),6.48(dd,J＝13.3,2.4Hz,1H),4.40(s,2H),3.57–3.49(m,1H),3.46–3.37(m,2H),3.15–3.05(m,2H),2.17–2.09(m,1H),1.84–1.74(m,2H),1.60–1.50(m,2H),1.23–1.18(m,2H),1.13–1.06(m,2H)。
从原料VII-29出发按照合成化合物1的合成方法合成化合物29。白色固体，收率60％； 1H NMR(400MHz,DMSO)δ7.69–7.61(m,2H),7.58–7.48(m,3H),6.91–6.80(m,2H),4.38(s,2H),3.55–3.43(m,3H),3.14–2.99(m,2H),2.37–2.27(m,1H),1.79–1.66(m,2H),1.43–1.30(m,2H),1.18–1.03(m,4H).MS(ESI,m/z)：561[M+H] +。
实施例30：
Figure PCTCN2020085713-appb-000076
实施例30合成路线如下：
Figure PCTCN2020085713-appb-000077
从原料V-9和IX-17出发按照合成化合物VII-10的合成方法合成化合物中间体VII-30。白色固体，收率62％； 1H NMR(400MHz,CDCl 3)δ7.57–7.49(m,2H),7.42–7.35(m,2H),6.31(d,J＝11.6Hz,2H),4.41(s,2H),3.59–3.51(m,1H),3.42–3.34(m,2H),3.19–3.08(m,2H),2.17–2.09(m,1H),1.82–1.73(m,2H),1.61–1.51(m,2H),1.24–1.20(m,2H),1.14–1.08(m,2H)。
从原料VII-30出发按照合成化合物1的合成方法合成化合物30。白色固体，收率64％； 1H NMR(400MHz,DMSO)δ7.69–7.62(m,2H),7.57–7.49(m,2H),6.79(d,J＝13.3Hz,2H),4.38(s,2H),3.57–3.45(m,3H),3.17–3.06(m,2H),2.40–2.25(m,1H),1.82–1.66(m,2H),1.44–1.28(m,2H),1.19–1.02(m,4H).MS(ESI,m/z)：579[M+H] +。
实施例31：
Figure PCTCN2020085713-appb-000078
实施例31合成路线如下：
Figure PCTCN2020085713-appb-000079
从原料去甲托品醇出发按照合成化合物IX-10的合成方法合成化合物中间体IX-31。白色固体，收率94％； 1H NMR(400MHz,CDCl 3)δ8.41(d,J＝1.8Hz,1H),7.58(dd,J＝9.0,2.3Hz,1H),6.49(d,J＝8.9Hz,1H),4.91–4.26(m,2H),4.12(t,J＝4.7Hz,1H),2.39(d,J＝7.3Hz,2H),2.18–2.04(m,4H),1.81(d,J＝14.3Hz,2H)；
从原料II-31出发按照合成化合物10的合成方法合成化合物V-31，其中
白色固体IV-31收率64％。 1H NMR(400MHz,CDCl 3)δ7.43–7.34(m,1H),7.00–6.91(m,2H),3.69(s,3H),2.92–2.83(m,1H),1.36–1.31(m,2H),1.25–1.20(m,2H)。
无色液体V-31收率82％。 1H NMR(400MHz,CDCl 3)δ7.54–7.44(m,1H),7.11–7.04(m,2H),4.33(s,2H),2.20–2.08(m,1H),1.34–1.17(m,4H).
从原料V-31和IX-13出发按照合成化合物VII-10的合成方法合成化合物中间体VII-31，白色固体，收率55％。 1H NMR(400MHz,CDCl 3)δ8.36(d,J＝2.1Hz,1H),7.53(dd,J＝9.0,2.1Hz,1H),7.49–6.39(m,1H),7.07–6.96(m,2H),6.42(d,J＝9.0Hz,1H),4.75–4.18(m,4H),3.48(t,J＝4.5Hz,1H),2.16–2.08(m,1H),1.99–1.92(m,2H),1.90–1.81(m,4H),1.69(d,J＝14.5Hz,2H),1.25–1.20(m,2H),1.14–1.08(m,2H).
从原料VII-31出发按照合成化合物1的合成方法合成化合物31，白色固体，收率76％。 1H NMR(400MHz,DMSO)δ8.46(d,J＝2.3Hz,1H),7.78(dd,J＝9.0,2.3Hz,1H),7.70–7.59(m,1H),7.29(t,J＝8.0Hz,2H),6.76(d,J＝9.0Hz,1H),4.41(s,2H),4.31(s,2H),3.45(s,1H),2.39–2.26(m,1H),1.86–1.68(m,6H),1.59(d,J＝14.4Hz,2H),1.19–1.03(m,4H).MS(ESI,m/z)：522[M+H] +。
实施例32：
Figure PCTCN2020085713-appb-000080
实施例32合成路线如下：
Figure PCTCN2020085713-appb-000081
从原料V-1和IX-31出发按照合成化合物VII-10的合成方法合成化合物中间体VII-32。白色固体，收率69％； 1H NMR(400MHz,CDCl 3)δ8.34(d,J＝2.1Hz,1H),7.51(dd,J＝9.0,2.1Hz,1H),7.42–7.38(m,2H),7.36–7.30(m,1H),6.41(d,J＝9.0Hz,1H),4.63–4.16(m,4H),3.46(t,J＝4.3Hz,1H),2.15–2.07(m,1H),1.97–1.91(m,2H),1.88–1.78(m,4H),1.70(d,J＝14.5Hz,2H),1.25–1.21(m,2H),1.14–1.07(m,2H)。
从原料VII-32出发按照合成化合物1的合成方法合成化合物32。白色固体，收率68％； 1H NMR(400MHz,DMSO)δ8.45(d,J＝2.3Hz,1H),7.78(dd,J＝9.0,2.3Hz,1H),7.68–7.60(m,2H),7.59–7.53(m,1H),6.77(d,J＝9.1Hz,1H),4.41(s,2H),4.26(s,2H),3.43(s, 1H),2.38–2.28(m,1H),1.86–1.54(m,8H),1.18–1.05(m,4H).MS(ESI,m/z)：554[M+H] +。
实施例33：
Figure PCTCN2020085713-appb-000082
实施例33合成路线如下：
Figure PCTCN2020085713-appb-000083
从原料V-8和IX-31出发按照合成化合物VII-10的合成方法合成化合物中间体VII-33。白色固体，收率73％； 1H NMR(400MHz,CDCl 3)δ8.32(d,J＝2.1Hz,1H),7.76(d,J＝7.3Hz,1H),7.63–7.53(m,2H),7.49(dd,J＝9.0,2.1Hz,1H),7.44–7.40(m,1H),6.39(d,J＝9.0Hz,1H),4.57–4.12(m,4H),3.42(t,J＝4.3Hz,1H),2.13–2.04(m,1H),1.98–1.91(m,2H),1.88–1.78(m,4H),1.69(d,J＝14.6Hz,2H),1.20–1.15(m,2H),1.11–1.05(m,2H)。
从原料VII-33出发按照合成化合物1的合成方法合成化合物33。白色固体，收率51％； 1H NMR(400MHz,DMSO)δ8.45(d,J＝2.3Hz,1H),7.92(d,J＝7.4Hz,1H),7.84–7.72(m,3H),7.60(d,J＝7.4Hz,1H),6.79(d,J＝9.1Hz,1H),4.19(s,2H),4.23(s,2H),3.43(s,1H),2.37–2.28(m,1H),1.82–1.69(m,6H),1.62(d,J＝14.4Hz,2H),1.17–1.05(m,4H).MS(ESI,m/z)：554[M+H] +。
实施例34：
Figure PCTCN2020085713-appb-000084
实施例34合成路线如下：
Figure PCTCN2020085713-appb-000085
从原料V-9和IX-31出发按照合成化合物VII-10的合成方法合成化合物中间体VII-34。白色固体，收率76％； 1H NMR(400MHz,CDCl 3)δ8.35(d,J＝2.1Hz,1H),7.58 –7.47(m,3H),7.40–7.35(m,2H),6.44–6.38(m,1H),4.57–4.23(m,4H),3.48(t,J＝4.5Hz,1H),7.16–2.06(m,1H),1.98–1.92(m,2H),1.90–1.82(m,4H),1.70(d,J＝14.5Hz,2H),1.22–1.18(m,2H),1.13–1.07(m,2H)。
从原料VII-34出发按照合成化合物1的合成方法合成化合物34。白色固体，收率66％； 1H NMR(400MHz,DMSO)δ8.47(d,J＝2.3Hz,1H),7.79(dd,J＝9.0,2.3Hz,1H),7.69–7.59(m,2H),7.56–7.49(m,2H),6.75(d,J＝9.1Hz,1H),4.41(s,2H),4.32(s,2H),3.47(s,1H),2.35–2.26(m,1H),1.86–1.68(m,6H),1.63(d,J＝14.4Hz,2H),1.15–1.02(m,4H).MS(ESI,m/z)：570[M+H] +。
实施例35：
Figure PCTCN2020085713-appb-000086
实施例35合成路线如下：
Figure PCTCN2020085713-appb-000087
从原料去甲托品醇出发按照合成化合物IX-10的合成方法合成化合物中间体IX-35。白色固体，收率64％； 1H NMR(400MHz,CDCl 3)δ7.42–7.34(m,1H),6.48(dd,J＝8.8,2.3Hz,1H),6.41(dd,J＝12.8,2.3Hz,1H),4.21(s,2H),4.09(t,J＝4.4Hz,1H),2.44–2.36(m,2H),2.18–2.05(m,4H),1.74(d,J＝13.9Hz,2H),1.66–1.59(m,1H)；
从原料V-31和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-35。白色固体，收率79％； 1H NMR(400MHz,CDCl 3)δ7.49–7.41(m,1H),7.37–7.30(m,1H),7.07–7.00(m,2H),6.44–7.31(m,2H),4.31(s,2H),4.06(s,2H),3.46(t,J＝4.5Hz,1H),2.16–2.08(m,1H),1.99–1.92(m,2H),1.91–1.82(m,4H),1.63(d,J＝14.5Hz,2H),1.25–1.20(m,2H),1.15–1.09(m,2H).。
从原料VII-35出发按照合成化合物1的合成方法合成化合物35。白色固体，收率66％； 1H NMR(400MHz,DMSO)δ7.70–7.59(m,1H),7.50(t,J＝8.6Hz,1H),7.29(t,J＝8.0Hz,2H),6.76–6.64(m,2H),4.31(s,2H),4.17(s,2H),3.43(s,1H),2.37–2.26(m,1H),1.83–1.67(m,6H),1.52(d,J＝14.5Hz,2H),1.16–1.04(m,4H).MS(ESI,m/z)：539[M+H] +。
实施例36：
Figure PCTCN2020085713-appb-000088
实施例36合成路线如下：
Figure PCTCN2020085713-appb-000089
从原料V-1和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-36。白色固体，收率73％； 1H NMR(400MHz,CDCl 3)δ7.46–7.41(m,2H),7.39–7.31(m,2H),6.42(dd,J＝8.8,2.1Hz,1H),6.35(d,J＝12.8Hz,1H),4.26(s,2H),4.07(s,2H),3.46(t,J＝4.4Hz,1H),2.17–2.08(m,1H),2.01–1.95(m,2H),1.91–1.82(m,4H),1.66(d,J＝14.7Hz,2H),1.29–1.24(m,2H),1.17–1.10(m,2H)。
从原料VII-36出发按照合成化合物1的合成方法合成化合物36。白色固体，收率65％； 1H NMR(400MHz,DMSO)δ7.65–7.59(m,2H),7.58–7.47(m,2H),6.69(t,J＝12.8Hz,2H),4.25(s,2H),4.17(s,2H),3.41(s,1H),2.38–2.27(m,1H),1.8.–1.68(m,6H),1.54(d,J＝14.5Hz,2H),1.17–1.05(m,4H).MS(ESI,m/z)：571[M+H] +。
实施例37：
Figure PCTCN2020085713-appb-000090
实施例37合成路线如下：
Figure PCTCN2020085713-appb-000091
从原料V-8和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-37。白色固体，收率74％； 1H NMR(400MHz,CDCl 3)δ7.84–7.79(m,1H),7.67–7.58(m,2H),7.48–7.42(m,1H),7.39–7.32(m,1H),6.45–6.31(m,2H),4.20(s,2H),4.08(s,2H),3.43(s,1H),2.14–2.07(m,1H),2.02–1.95(m,2H),1.94–1.83(m,4H),1.66(d,J＝14.7Hz,2H),1.29–1.23(m,2H),1.16–1.09(m,2H)。
从原料VII-37出发按照合成化合物1的合成方法合成化合物37。白色固体，收率61％； 1H NMR(400MHz,DMSO)δ7.91(d,J＝7.6Hz,1H),7.83–7.70(m,2H),7.60(d,J＝7.4Hz,1H),7.50(t,J＝8.6Hz,1H),6.75–6.64(m,2H),4.26–4.13(m,4H),3.40(s,1H),2.38 –2.24(m,1H),1.83–1.69(m,6H),1.55(d,J＝14.5Hz,2H),1.18–1.03(m,4H).MS(ESI,m/z)：571[M+H] +。
实施例38：
Figure PCTCN2020085713-appb-000092
实施例38合成路线如下：
Figure PCTCN2020085713-appb-000093
从原料V-9和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-38。白色固体，收率74％； 1H NMR(400MHz,CDCl 3)δ7.58–7.50(m,2H),7.43–7.37(m,2H),7.34(t,J＝8.2Hz,1H),6.42(dd,J＝8.8,2.2Hz,1H),6.35(dd,J＝12.8,2.2Hz,1H),4.34(s,2H),4.06(s,2H),3.47(t,J＝4.5Hz,1H),2.16–2.07(m,1H),2.00–1.94(m,2H),1.92–1.84(m,4H),1.64(d,J＝14.5Hz,2H),1.26–1.20(m,2H),1.15–1.09(m,2H)。
从原料VII-38出发按照合成化合物1的合成方法合成化合物38。白色固体，收率67％； 1H NMR(400MHz,DMSO)δ7.71–7.60(m,2H),7.58–7.46(m,3H),6.77–6.64(m,2H),4.32(s,2H),4.19(s,2H),3.45(s,1H),2.37–2.27(m,1H),1.86–1.69(m,6H),1.56(d,J＝14.5Hz,2H),1.17–1.04(m,4H).MS(ESI,m/z)：587[M+H] +。
实施例39：
Figure PCTCN2020085713-appb-000094
实施例39合成路线如下：
Figure PCTCN2020085713-appb-000095
Figure PCTCN2020085713-appb-000096
从原料II-39出发按照合成化合物10的合成方法合成化合物V-39，其中
白色固体IV-39收率54％。 1H NMR(400MHz,CDCl 3)δ7.52–7.44(m,2H),7.32–7.26(m,1H),7.21(d,J＝8.5Hz,1H),6.46(t,J＝73.7Hz,1H),3.72(s,3H),2.88–2.80(m,1H),1.37–1.32(m,2H),1.26–1.22(m,2H)。
无色液体V-39收率72％。 1H NMR(400MHz,CDCl 3)δ7.60–7.51(m,2H),7.41–7.32(m,2H),6.51(t,J＝73.7Hz,1H),4.38(s,2H),2.18–2.10(m,1H),1.32–1.17(m,4H).
从原料V-39和IX-31出发按照合成化合物VII-10的合成方法合成化合物中间体VII-39，白色固体，收率61％。 1H NMR(400MHz,CDCl 3)δ8.37(d,J＝2.2Hz,1H),7.57–7.45(m,3H),7.35–7.24(m,2H),6.47(t,J＝74.1Hz,1H),6.42(d,J＝8.9Hz,1H),4.34(s,4H),3.49(t,J＝4.5Hz,1H),2.16–2.08(m,1H),2.00–1.94(m,2H),1.90–1.82(m,4H),1.72(d,J＝14.4Hz,2H),1.23–1.20(m,2H),1.14–1.07(m,2H).
从原料VII-39出发按照合成化合物1的合成方法合成化合物39，白色固体，收率78％。 1H NMR(400MHz,DMSO)δ8.46(d,J＝2.3Hz,1H),7.79(dd,J＝9.0,2.3Hz,1H),7.64–7.55(m,1H),7.54–7.49(m,1H),7.40–7.33(m,2H),7.23(d,J＝73.6Hz,1H),6.77(d,J＝9.0Hz,1H),4.55–4.23(m,4H),3.46(s,1H),2.36–2.27(m,1H),1.86–1.69(m,6H),1.62(d,J＝14.4Hz,2H),1.15–1.05(m,4H).MS(ESI,m/z)：552[M+H] +。
实施例40：
Figure PCTCN2020085713-appb-000097
实施例40合成路线如下：
Figure PCTCN2020085713-appb-000098
从原料II-40出发按照合成化合物10的合成方法合成化合物V-40，其中
白色固体IV-40收率54％。 1H NMR(400MHz,CDCl 3)δ7.42–7.31(m,2H),7.30–7.24(m,2H),3.69(s,3H),2.95–2.87(m,1H),2.23(s,3H),1.42–1.36(m,2H),1.30–1.23(m,2H)。
无色液体V-39收率72％。 1H NMR(400MHz,CDCl 3)δ7.42–7.29(m,4H),4.27(s,2H),2.33(s,3H),2.19–2.10(m,1H),1.32–1.27(m,2H),1.23–1.16(m,2H).
从原料V-40和IX-31出发按照合成化合物VII-10的合成方法合成化合物中间体VII-40，白色固体，收率61％。 1H NMR(400MHz,CDCl 3)δ8.37(d,J＝1.8Hz,1H),7.54(dd,J＝8.8,2.3Hz,1H),7.37–7.22(m,4H),6.43(d,J＝8.8Hz,1H),4.76–4.30(m,2H),4.20(s,2H),3.49(t,J＝4.4Hz,1H),2.30(s,3H),2.16–2.10(m,1H),2.07–2.02(m,2H),1.93–1.83(m,4H),1.77(d,J＝14.3Hz,2H),1.26–1.21(m,2H),1.15–1.08(m,2H).
从原料VII-40出发按照合成化合物1的合成方法合成化合物40，白色固体，收率78％。 1H NMR(400MHz,DMSO)δ8.47(d,J＝2.3Hz,1H),7.79(dd,J＝9.0,2.3Hz,1H),7.39–7.24(m,4H),6.75(d,J＝9.0Hz,1H),4.43(s,2H),4.19(s,2H),3.45(s,1H),2.33–2.24(m,1H),2.21(s,3H),1.92–1.64(m,8H),1.13–1.04(m,4H).MS(ESI,m/z)：500[M+H] +。
实施例41：
Figure PCTCN2020085713-appb-000099
实施例41合成路线如下：
Figure PCTCN2020085713-appb-000100
从原料V-41和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-41，白色固体，收率64％。 1H NMR(400MHz,CDCl 3)δ7.55–7.48(m,2H),7.38–7.29(m,3H),6.47(t,J＝74.1Hz,1H),6.45–6.40(m,1H),6.38–6.32(m,1H),4.34(s,2H),4.10–4.03(m,2H),3.52–3.44(m,1H),2.16–2.09(m,1H),2.00–1.95(m,2H),1.92–1.85(m,4H),1.65(d,J＝15.2Hz,2H),1.25–1.22(m,2H),1.15–1.09(m,2H).
从原料VII-39出发按照合成化合物1的合成方法合成化合物39，白色固体，收率71％。 1H NMR(400MHz,DMSO)δ7.60(td,J＝8.3,1.7Hz,1H),7.54–7.46(m,2H),7.40–7.34(m,2H),7.23(t,J＝73.6Hz,1H),6.78–6.62(m,2H),4.32(s,2H),4.18(s,2H),3.43(s,1H),2.37–2.27(m,1H),1.86–1.69(m,6H),1.55(d,J＝14.5Hz,2H),1.17–1.02(m,4H).MS(ESI,m/z)：569[M+H] +。
实施例42：
Figure PCTCN2020085713-appb-000101
实施例42合成路线如下：
Figure PCTCN2020085713-appb-000102
从原料V-40和IX-35出发按照合成化合物VII-10的合成方法合成化合物中间体VII-42，白色固体，收率49％。 1H NMR(400MHz,CDCl 3)δ7.28–7.23(m,2H),7.33–7.29(m,2H),7.28–7.23(m,1H),6.46–6.41(m,1H),6.39–6.34(m,1H),4.21(s,2H),4.13–4.06(m,2H),3.50–3.43(m,1H),2.31(s,3H),2.07(s,3H),1.97–1.86(m,4H),1.75–1.67(m,2H),1.29–1.23(m,2H),1.16–1.09(m,2H).
从原料VII-40出发按照合成化合物1的合成方法合成化合物40，白色固体，收率61％。 1H NMR(400MHz,CDCl 3)δ7.66(t,J＝8.7Hz,1H),7.37–7.22(m,4H),6.52(dd,J＝9.0,1.9Hz,1H),6.39(dd,J＝14.9,1.9Hz,1H),4.20(s,2H),4.09(s,2H),3.49–3.43(m,1H),2.30(s,3H),2.17–2.01(m,3H),1.92(dd,J＝9.6,3.4Hz,4H),1.69(d,J＝14.5Hz,2H),1.28–1.20(m,2H),1.17–1.08(m,2H).MS(ESI,m/z)：517[M+H] +。
药理实验实施例
FXR分子水平活性测试方法
利用重组GST-FXR融合蛋白，通过Perkin Elmer公司的AlphaScreen检测试剂测定FXR活性。该方法的反应是在384孔板中，反应总体积是15μL。蛋白、激动剂、辅调节因子、AlphaScreen
Figure PCTCN2020085713-appb-000103
受体微珠和AlphaScreen
Figure PCTCN2020085713-appb-000104
供体微珠的混合液在包含：Tris-HCl 50mM(pH7.4)，50mM NaCl，BSA 0.1％，1mM DTT的缓冲液中进行反应，通过荧光检测仪Envision检测在570nm波长下的荧光信号强度反应FXR活性。EC 50的值通过软件Graphpad Prism 5计算得到。
FXR细胞水平活性测试方法
将FXR表达质粒和FXRE luciferase报告质粒以1:9的比例共转染至293T细胞后，以5*10 5/孔将被转染细胞接种于96孔平底微孔板(ViewPlate-96,White 96-well Microplate with Clear Bottom，PerkinElmer)。培养细胞24h确保质粒表达，加入待测FXR受体激动剂；待测化合物作用18h后，使用luciferase kit(steady-Glo Luciferase Assay system)检测荧光强弱以反映化合物对FXR受体的激活效率。
Figure PCTCN2020085713-appb-000105
其中初筛时，待测化合物和两个阳性化合物OCA、GW4064以10μM作用于细胞，分别测定待测化合物对两个阳性化合物的相对活性(相对活性＝(待测化合物信号强度-blank)/(阳性化合物信号强度-blank)*100％)，相对活性高于阳性化合物50％的化合物进入复筛，选择合适浓度区间，计算其剂量依赖关系，即EC 50值。
表1活性测试结果
Figure PCTCN2020085713-appb-000106
Figure PCTCN2020085713-appb-000107
结论：测试结果表明本发明所述化合物在分子水平和细胞水平对FXR均有不错的激动能力，其中多个化合物活性明显优于两个阳性对照。
体内肝纤维化药理活性测试
1)化合物1(LXF-32)对TAA诱导的肝纤维化模型大鼠的药效学评价
本实验采用TAA诱导肝纤维化模型大鼠，考察化合物1长期口服给药对该模型大鼠肝纤维化的影响。
实验方法：雄性SD大鼠按150mg/kg剂量一周三次腹腔注射硫代乙酰胺(TAA，溶于生理盐水)诱导肝纤维化模型。造模四周后，对大鼠进行眼球后静脉丛取血，检测血清ALP指标，根据ALP、体重等指标，将大鼠随机分为3组，每组8只，分别为模型对照组(Vehicle)、化合物1组(20mg/kg)、阳性化合物OCA组(20mg/kg)等，口服灌胃给药，一天一次。给药期间监测动物摄食和体重，给药2周后对大鼠进行眼球后静脉丛取血，检测血清ALP指标，给药4周眼球后静脉丛取血后脱臼处死大鼠，取肝脏称量肝重后取部分肝脏用4％多聚甲醛固定，部分肝脏-80℃冻存。整个实验过程中另设8只同窝大鼠腹腔注射相同体积的生理盐水作为系统正常对照组(WT)。该实验通过检测血清中肝功能指标ALP水平、肝脏中α-SMA及Col1α1(纤维化相关基因)基因水平的表达、肝脏中羟脯氨酸(胶原特征性氨基酸)含量及肝脏病理学改变(天狼猩红染色)等指标反映化合物是否具有缓解肝纤维化的作用。
研究结果表明，本发明的化合物1给药4周能够显著降低血清中ALP水平、降低肝脏组织中羟脯氨酸的含量、显著下调肝脏组织中α-SMA及Col1α1 mRNA表达(图1)；对天狼猩红染色的肝脏病理切片的定量分析中，化合物1能减少肝脏中胶原含量，因模型组组内差异大，无统计学差异(图2)。
综上所述，本发明的化合物1(LXF-32)长期给药能明显改善TAA诱导肝纤维化大鼠的肝功能，下调α-SMA及Col1α1 mRNA表达，减少肝脏中胶原的沉积，对肝纤维化有一定的缓解作用。
2)化合物8(LXF-116)对CCL4诱导的肝纤维化模型小鼠的药效学评价
本实验采用CCl4诱导肝纤维化模型小鼠，考察化合物化合物8长期口服给药对该模型小鼠肝纤维化的影响。
实验方法：雄性C57BL/6j小鼠按2mL/kg、10％CCl4(溶于橄榄油)一周三次腹腔注射诱导肝纤维化模型。造模两周后，对小鼠进行眼球后静脉丛取血，检测血清ALT、AST、TBA、LDH指标，根据ALT、AST、TBA、LDH、体重等指标，将小鼠随机分为5组，每组10只，分别为模型对照组(Vehicle)、化合物8低剂量组(6mg/kg)，化合物8高剂量组(20mg/kg)、阳性化合物OCA低剂量组(6mg/kg)，OCA高剂量组(20mg/kg)等，口服灌胃给药，一天一次。给药期间监测动物摄食和体重，给药3周后对小鼠进行眼球后静脉丛取血，检测血清ALT、AST、TBA、LDH、指标，给药6周眼球后静脉丛取血后脱臼处死小鼠，取肝脏称量肝重后取部分肝脏用4％多聚甲醛固定，部分肝脏-80℃冻存。整个实验过程中另设10只同窝小鼠腹腔注射相同体积的橄榄油作为系统正常对照组(WT)。该实验通过检测血清中肝功能指标ALT、AST、TBA、LDH水平、肝脏中α-SMA及Col1α1基因水平的表达及肝脏病理学改变(天狼猩红染色)等指标反映化合物是否具有缓解肝纤维化的作用。
研究结果表明，本发明的化合物8高低剂量组给药6周均能显著降低血清中ALT、AST、TBA的水平，对LDH影响不大；阳性化合物OCA高剂量组能显著降低血清中ALT、AST、TBA的水平，低剂量组仅对TBA有降低作用；化合物8低剂量的效果略优于OCA的低剂量组(图3)。化合物8高剂量组能显著下调肝脏中α-SMA表达，下调肝脏中col1α1表达(图4)；对天狼猩红染色的肝脏病理切片的定量分析中，化合物8高低剂量组均能显著减少肝脏中胶原含量，化合物8低剂量的效果略优于OCA的低剂量组(图5)。
综上所述，本发明的化合物8(LXF-116)长期给药能明显改善CCl4诱导肝纤维化小鼠的肝功能，下调α-SMA及Col1α1 mRNA表达，减少肝脏中胶原的沉积，对肝纤维化有较好的缓解作用。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐，
    Figure PCTCN2020085713-appb-100001
    其中，R 11、R 12、R 13、R 14、R 15各自独立地为氢、卤素、卤代C 1-6烷基、卤代C 1-C 6烷氧基、C 1-C 6烷基、C 1-6烷氧基、C 3-C 6环烷基、C 3-C 6环烷氧基、氰基或硝基；
    R 2为C 6-C 12芳基、C 1-C 6烷基或C 3-C 6环烷基；
    Q为4-8元杂环基；
    A为取代或未取代的以下基团：苯基、吡啶基、噻吩基、呋喃基、吲唑基、吲哚基、苯并噻吩基、苯并呋喃基，所述取代是指具有选自下组的一个两个、或三个取代基：卤素、C 1-C 6烷基、卤代C 1-6烷基、卤代C 1-C 6烷氧基、C 3-C 6环烷基、C 1-C 6烷氧基、C 3-C 6环烷氧基；
    X为O或S。
  2. 如权利要求1所述的化合物，其特征在于，R 11、R 12、R 13、R 14、R 15各自独立地为氢、氟、氯、溴、甲基、乙基、正丙基、异丙基、正丁基、异丁基、三氟甲基、或三氟甲氧基。
  3. 如权利要求1所述的化合物，其特征在于，R 2为苯基、甲基、乙基、正丙基、异丙基、正丁基、异丁基、环丙基、环丁基或环戊基。
  4. 如权利要求1所述的化合物，其特征在于，Q为4-7元含氮杂环基。
  5. 如权利要求1所述的化合物，其特征在于，A为取代或未取代的以下基团：苯基、吡啶基、噻吩基、呋喃基、吲唑基、吲哚基、苯并噻吩基、苯并呋喃基，所述取代是指具有选自下组的一个或两个取代基：氟、氯、溴、C 1-C 4烷基、C 3-C 6环烷基、C 1-C 4烷氧基、C 3-C 6环烷氧基。
  6. 如权利要求1所述的化合物，其特征在于，所述化合物为：
    Figure PCTCN2020085713-appb-100002
    Figure PCTCN2020085713-appb-100003
  7. 如权利要求1所述的化合物的制备方法，其特征在于，所述制备方法包括以下步骤：
    Figure PCTCN2020085713-appb-100004
    (a’)通式VII所示的化合物与盐酸羟胺反应生成通式VIII所示的化合物；
    (b’)通式VIII所示的化合物在光气、三光气、羰基二咪唑或者硫羰基二咪唑的作用下反应生成通式I所示的化合物，
    其中，X、R 2、Q、A、R 11、R 12、R 13、R 14、R 15的定义如权利要求1所述。
  8. 如权利要求7所述的化合物的制备方法，其特征在于，通式VII所示的化合物通过以下步骤制备：
    Figure PCTCN2020085713-appb-100005
    a)以取代苯甲醛通式II所示的化合物为起始原料，与盐酸羟胺反应得到中间体后用N-氯代丁二酰亚胺(NCS)氯代后成通式III所示的化合物；
    b)然后将通式III所示的化合物与3-氧代丙酸酯反应得到通式IV所示的化合物；
    c)将通式IV所示的化合物中的酯还原下生成醇，再进行溴代后生成V所示的化合物，
    d)通式V所示的化合物与Q-OH反应成通式VI所示的化合物；
    e)通式VI所示的化合物在铜或者钯的催化下与Br-A-CN偶联得通式VII所示的化合物；
    或者通过以下步骤制备：
    Figure PCTCN2020085713-appb-100006
    f)Q-OH与F-A-CN反应生成通式IX所示的化合物；
    g)通式V所示的化合物与通式IX所示的化合物反应生产通式VII所示的化合物，
    各式中，R 2、Q、A、R 11、R 12、R 13、R 14、R 15的定义如权利要求1所述。
  9. 一种药物组合物，包含：
    权利要求1所述的通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐；和
    药学上可接受的载体。
  10. 权利要求1所述的通式I所示的化合物，或其对映异构体、非对映异构体、互变异构体、外消旋体、溶剂合物、前药或其药学上可接受的盐的用途，其特征在于，
    (a)用作FXR激动剂；
    (b)用于制备用于治疗FXR相关疾病的药物；
    (c)用于降低血清中ALP、ALT、AST、TBA的水平；
    (d)用于降低肝脏组织中羟脯氨酸的含量；
    (e)用于下调肝脏组织中α-SMA及Col1α1 mRNA表达；或
    (f)用于减少肝脏中胶原含量。
PCT/CN2020/085713 2019-04-19 2020-04-20 Fxr小分子激动剂及其制备方法和用途 WO2020211872A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP20791301.3A EP3957640A4 (en) 2019-04-19 2020-04-20 FXR SMALL MOLECULE AGONIST AND METHOD OF MANUFACTURE THEREOF AND USE THEREOF
CA3137198A CA3137198C (en) 2019-04-19 2020-04-20 Fxr small molecule agonist and preparation method therefor and use thereof
US17/603,823 US20220213083A1 (en) 2019-04-19 2020-04-20 Fxr small molecule agonist and preparation method therefor and use thereof
SG11202111502XA SG11202111502XA (en) 2019-04-19 2020-04-20 Fxr small molecule agonist and preparation method therefor and use thereof
AU2020257379A AU2020257379B2 (en) 2019-04-19 2020-04-20 FXR small molecule agonist and preparation method therefor and use thereof
EA202192872A EA202192872A1 (ru) 2019-10-12 2020-04-20 Низкомолекулярные агонисты fxr, их способ получения и применение
KR1020217037613A KR20220003558A (ko) 2019-04-19 2020-04-20 Fxr 소분자 작용제 및 이의 제조 방법과 용도
BR112021020681A BR112021020681A2 (pt) 2019-04-19 2020-04-20 Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo
MX2021012750A MX2021012750A (es) 2019-04-19 2020-04-20 Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
JP2021562184A JP7398605B2 (ja) 2019-04-19 2020-04-20 Ｆｘｒ小分子アゴニストとその調製方法および用途
IL287159A IL287159A (en) 2019-04-19 2021-10-11 Agonistic small molecules for fxr (farnesoid x receptor) and a method for their preparation and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910319757.X 2019-04-19
CN201910319757 2019-04-19
CN201910969552.6 2019-10-12
CN201910969552.6A CN111825667B (zh) 2019-04-19 2019-10-12 Fxr小分子激动剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2020211872A1 true WO2020211872A1 (zh) 2020-10-22

Family

ID=72837054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/085713 WO2020211872A1 (zh) 2019-04-19 2020-04-20 Fxr小分子激动剂及其制备方法和用途

Country Status (9)

Country Link
US (1) US20220213083A1 (zh)
EP (1) EP3957640A4 (zh)
JP (1) JP7398605B2 (zh)
KR (1) KR20220003558A (zh)
BR (1) BR112021020681A2 (zh)
IL (1) IL287159A (zh)
MX (1) MX2021012750A (zh)
SG (1) SG11202111502XA (zh)
WO (1) WO2020211872A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2022068815A1 (zh) * 2020-09-30 2022-04-07 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
WO2022147448A1 (en) * 2020-12-30 2022-07-07 Terns Pharmaceuticals, Inc. Compounds and methods for modulating fxr
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
JP2023120086A (ja) * 2022-02-17 2023-08-29 カスケード ファーマシューティカルズ、インコーポレーテッド 新型ｆｘｒ小分子作動剤の製造およびその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4245365A1 (en) * 2022-03-16 2023-09-20 Cascade Pharmaceuticals, Inc. A fxr small molecule agonist, the preparation and use thereof
US20230295141A1 (en) * 2022-03-17 2023-09-21 Cascade Pharmaceuticals, Inc. Fxr small molecule agonist, the preparation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108064223A (zh) * 2014-12-17 2018-05-22 吉利德科学公司 含羟基的fxr(nr1h4)调节化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CN116854681A (zh) * 2016-08-23 2023-10-10 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064223A (zh) * 2014-12-17 2018-05-22 吉利德科学公司 含羟基的fxr(nr1h4)调节化合物
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
WO2018085148A1 (en) * 2016-11-04 2018-05-11 Hepagene Therapeutics, Inc. Nitrogen-containing heterocyclic compounds as fxr modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP3957640A4

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2022068815A1 (zh) * 2020-09-30 2022-04-07 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
WO2022147448A1 (en) * 2020-12-30 2022-07-07 Terns Pharmaceuticals, Inc. Compounds and methods for modulating fxr
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
JP2023120086A (ja) * 2022-02-17 2023-08-29 カスケード ファーマシューティカルズ、インコーポレーテッド 新型ｆｘｒ小分子作動剤の製造およびその使用
JP7450951B2 (ja) 2022-02-17 2024-03-18 カスケード ファーマシューティカルズ、インコーポレーテッド 新型ｆｘｒ小分子作動剤の製造およびその使用

Also Published As

Publication number Publication date
US20220213083A1 (en) 2022-07-07
MX2021012750A (es) 2021-11-18
JP7398605B2 (ja) 2023-12-15
SG11202111502XA (en) 2021-11-29
KR20220003558A (ko) 2022-01-10
JP2022529296A (ja) 2022-06-20
EP3957640A1 (en) 2022-02-23
BR112021020681A2 (pt) 2021-12-07
IL287159A (en) 2021-12-01
EP3957640A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
WO2020211872A1 (zh) Fxr小分子激动剂及其制备方法和用途
CN108602811B (zh) Fxr受体激动剂
JP5715713B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子
WO2020034988A1 (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
CN107428752A (zh) 自家趋化素抑制性化合物
TWI811243B (zh) 灰黃黴素化合物及醫藥用途
DK2599774T3 (en) DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands
CN115867556A (zh) Lpa受体拮抗剂及其用途
CN106565674B (zh) 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
CA3137198C (en) Fxr small molecule agonist and preparation method therefor and use thereof
WO2022068815A1 (zh) Fxr小分子激动剂及其制备方法和用途
TWI404709B (zh) 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
WO2022057672A1 (zh) 新型fxr小分子激动剂制备及其用途
CN114195776A (zh) 新型fxr小分子激动剂制备及其用途
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
EA046249B1 (ru) Низкомолекулярные агонисты fxr, их способ получения и применение
CA3129619A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
JP7450951B2 (ja) 新型ｆｘｒ小分子作動剤の製造およびその使用
KR20180023419A (ko) (r)-(1-메틸피롤리딘-3-일)메틸(3&#39;-클로로-4&#39;-플루오로-[1,1&#39;-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
EP4245365A1 (en) A fxr small molecule agonist, the preparation and use thereof
US20230295141A1 (en) Fxr small molecule agonist, the preparation and use thereof
AU2020221371A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
TW202325305A (zh) ２－（芳基－２－基）嗎啉及其氘代衍生物、製備方法和應用
CN114315844A (zh) 一类fxr调节剂及其制备方法和用途
JP2010195688A (ja) Ｎｐｙｙ５受容体拮抗作用を有するアミド及びウレア誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20791301

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3137198

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021562184

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021020681

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217037613

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2020257379

Country of ref document: AU

Date of ref document: 20200420

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2020791301

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112021020681

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211015